WO2008096164A2 - Treatment fluids comprising diutan and associated methods - Google Patents

Treatment fluids comprising diutan and associated methods Download PDF

Info

Publication number
WO2008096164A2
WO2008096164A2 PCT/GB2008/000474 GB2008000474W WO2008096164A2 WO 2008096164 A2 WO2008096164 A2 WO 2008096164A2 GB 2008000474 W GB2008000474 W GB 2008000474W WO 2008096164 A2 WO2008096164 A2 WO 2008096164A2
Authority
WO
WIPO (PCT)
Prior art keywords
fluid
acid
treatment fluid
mgal
clarified diutan
Prior art date
Application number
PCT/GB2008/000474
Other languages
French (fr)
Other versions
WO2008096164A3 (en
Inventor
Thomas D. Welton
Richard W. Pauls
Lulu Song
Jason E. Bryant
Sean R. Beach
Ian D. Robb
Original Assignee
Halliburton Energy Services, Inc.
Curtis, Philip, Anthony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halliburton Energy Services, Inc., Curtis, Philip, Anthony filed Critical Halliburton Energy Services, Inc.
Priority to BRPI0807216-7A2A priority Critical patent/BRPI0807216A2/en
Priority to AU2008212688A priority patent/AU2008212688B2/en
Priority to CN200880010376.3A priority patent/CN101675141B/en
Priority to CA2677462A priority patent/CA2677462C/en
Priority to EP08709370A priority patent/EP2118233A2/en
Publication of WO2008096164A2 publication Critical patent/WO2008096164A2/en
Publication of WO2008096164A3 publication Critical patent/WO2008096164A3/en

Links

Classifications

    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17DPIPE-LINE SYSTEMS; PIPE-LINES
    • F17D1/00Pipe-line systems
    • F17D1/08Pipe-line systems for liquids or viscous products
    • F17D1/16Facilitating the conveyance of liquids or effecting the conveyance of viscous products by modification of their viscosity
    • F17D1/17Facilitating the conveyance of liquids or effecting the conveyance of viscous products by modification of their viscosity by mixing with another liquid, i.e. diluting
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K8/00Compositions for drilling of boreholes or wells; Compositions for treating boreholes or wells, e.g. for completion or for remedial operations
    • C09K8/60Compositions for stimulating production by acting on the underground formation
    • C09K8/62Compositions for forming crevices or fractures
    • C09K8/66Compositions based on water or polar solvents
    • C09K8/68Compositions based on water or polar solvents containing organic compounds
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K8/00Compositions for drilling of boreholes or wells; Compositions for treating boreholes or wells, e.g. for completion or for remedial operations
    • C09K8/60Compositions for stimulating production by acting on the underground formation
    • C09K8/62Compositions for forming crevices or fractures
    • C09K8/72Eroding chemicals, e.g. acids

Definitions

  • the present invention relates to methods and compositions for use in industrial, oilfield, and/or subterranean operations. More particularly, the present invention relates to treatment fluids comprising clarified diutan gelling agents, and their use in industrial, oilfield, geothermal, coal, coal bed methane, and/or subterranean operations.
  • Treatment fluids may be used in a variety of subterranean treatments, including, but not limited to, stimulation treatments, damage removal, formation isolation, wellbore cleanout, scale removal, scale control, drilling operations, cementing, conformance treatments, and sand control treatments. Treatment fluids may also be used in a variety of pipeline treatments.
  • treatment or “treating,” refers to any operation that uses a fluid in conjunction with a desired function and/or for a desired purpose.
  • the term “treatment,” or “treating,” does not imply any particular action by the fluid or any particular component thereof.
  • Hydraulic fracturing operations generally involve pumping a treatment fluid (e.g., a fracturing fluid) into a well bore that penetrates a subterranean formation at a sufficient hydraulic pressure to create or enhance one or more cracks, or "fractures,” in the subterranean formation.
  • a treatment fluid e.g., a fracturing fluid
  • fractures e.g., fractures
  • Endhancing one or more fractures in a subterranean formation, as that term is used herein, is defined to include the extension or enlargement of one or more natural or previously created fractures in the subterranean formation.
  • the treatment fluid may comprise particulates ⁇ often referred “ to as "proppant " particulates,” that are deposited in the fractures.
  • the proppant particulates may prevent the fractures from fully closing upon the release of hydraulic pressure, forming conductive channels through which fluids may flow to the well bore.
  • the proppant particulates also may be coated with certain types of materials, including resins, tackifying agents, and the like, among other purposes, to enhance conductivity (e.g., fluid flow) through the fractures in which they reside.
  • treatment fluids are acidizing operations. Where the subterranean formation comprises acid-soluble components, such as those present in carbonate and sandstone formations, stimulation and/or damage removal is often achieved by contacting the formation with a treatment fluid that comprises an acid. For example, where hydrochloric acid contacts and reacts with calcium carbonate in a formation, the calcium carbonate is consumed to produce water, carbon dioxide, and calcium chloride.
  • the water and salts dissolved therein may be recovered by producing them to the surface (e.g., "flowing back" the well), leaving a desirable amount of voids (e.g., wormholes) within the formation, which may enhance the formation's permeability and/or increase the rate at which hydrocarbons subsequently may be produced from the formation.
  • One method of acidizing known as “fracture acidizing” comprises injecting a treatment fluid that comprises an acid into the formation at a pressure sufficient to create or enhance one or more fractures within the subterranean formation.
  • matrix acidizing comprises injecting a treatment fluid that comprises an acid into the formation at a pressure below that which would create or enhance one or more fractures within the subterranean formation.
  • Treatment fluids are also utilized in sand control treatments, such as gravel packing.
  • a treatment fluid suspends particulates (commonly referred to as “gravel particulates”), and deposits at least a portion of those particulates in a desired area in a well bore, e.g., near unconsolidated or weakly consolidated formation zones, to form a "gravel pack,” which is a grouping of particulates that are packed sufficiently close together so as to prevent the passage of certain materials through the gravel pack.
  • This "gravel pack” may, inter alia, enhance sand control in the subterranean formation and/or prevent the flow of particulates from an unconsolidated portion of the subterranean formation (e.g., a propped fracture) into a well bore.
  • One common type of gravel-packing operation involves placing a sand control screen in the well bore and packing the annulus between the screen and the well bore with the gravel particulates of a specific size designed to prevent the passage of formation sand.
  • the gravel particulates act, inter alia, to prevent the formation sand from occluding the screen or migrating with the produced hydrocarbons, and the screen acts, inter alia, to prevent the particulates from entering the well bore.
  • the gravel particulates also may be coated with certain types of materials, including resins, tackifying agents, and the like, among other purposes, to enhance conductivity (e.g., fluid flow) through the gravel pack in which they reside.
  • conductivity e.g., fluid flow
  • the viscosity of the treatment fluid may be reduced to allow it to be recovered.
  • fracturing and gravel-packing treatments are combined into a single treatment (commonly referred to as "FracPacTM" operations).
  • the treatments are generally completed with a gravel pack screen assembly in place with the hydraulic fracturing treatment being pumped through the annular space between the casing and screen.
  • the hydraulic fracturing treatment ends in a screen-out condition, creating an annular gravel pack between the screen and casing.
  • the fracturing treatment may be performed prior to installing the screen and placing a gravel pack.
  • Maintaining sufficient viscosity in the treatment fluids used in these operations is important for a number of reasons. Maintaining sufficient viscosity is important in fracturing and sand control treatments for particulate transport and/or to create or enhance fracture width. Also, maintaining sufficient viscosity may be important in acid treatments, in friction reduction and to control and/or reduce fluid loss into the formation. Moreover, a treatment fluid of a sufficient viscosity may be used to divert the flow of fluids present within a subterranean fo ⁇ nation (e.g., formation fluids, other treatment fluids) to other portions of the formation, for example, by invading the higher permeability portions of the formation with a fluid that has high viscosity at low shear rates.
  • a subterranean fo ⁇ nation e.g., formation fluids, other treatment fluids
  • crosslinking agents usually comprise a metal complex or compound that interacts with at least two polymer molecules to form a "crosslink” between them.
  • polymeric gelling agents commonly are added to the treatment fluids.
  • examples of commonly used polymeric gelling agents include, but are not limited to, biopolymers, polysaccharides such as guar gums and derivatives thereof, cellulose derivatives, synthetic polymers, and the like. These gelling agents, when hydrated and at a sufficient concentration, are capable of forming a viscous solution.
  • a gelling agent is combined with an aqueous fluid and the soluble portions of the gelling agent are dissolved in the aqueous fluid, thereby increasing the viscosity of the fluid.
  • the insoluble portions of the gelling agents such as proteins, cellulose and fibers, remain in the aqueous fluid and enter the pores of the subterranean zones being treated as well as gravel packs and proppant packs in the zones.
  • the presence of this residue may impair the producing capabilities and/or the permeability of the subterranean formation and is therefore undesirable.
  • viscosified treatment fluids may be desirable because of their advantageous properties, such as sand transport properties, long-lasting viscosity, desirable sheer thinning characteristics, and efficient breaking properties, it may not be practicable to use such gelling agents if the aqueous base fluid is a brine.
  • the term "brine” as used herein refers to various salts and salt mixtures dissolved in aqueous fluids.
  • the insoluble portions of the gelling agents may agglomerate in the presence of certain salts, such as potassium chloride, thereby making it difficult to achieve the desired viscosity.
  • certain salts such as potassium chloride
  • the agglomeration of insoluble portions of the gelling agent may also prevent effective filtration of the viscosified fluid.
  • the present invention relates to methods and compositions for use in industrial, oilfield, and/or subterranean operations. More particularly, the present invention relates to treatment fluids comprising clarified diutan gelling agents, and their use in industrial, oilfield, geothermal, coal, coal bed methane, and/or subterranean operations.
  • the present invention provides a treatment fluid comprising a base fluid and a gelling agent that comprises clarified diutan.
  • the present invention provides a subterranean treatment fluid comprising a base fluid, a gelling agent that comprises clarified diutan, and an acid composition.
  • the present invention prvides a subterranean treatment fluid comprising a base fluid, a gelling agent that comprises clarified diutan, and at least a plurality of particulates.
  • the present invention provides a method comprising providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; and introducing the acidic treatment fluid into at least a portion of a subterranean formation.
  • the present invention provides a method comprising providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; contacting a portion of a subterranean formation with the acidic treatment fluid; and allowing the acidic treatment fluid to interact with a component of the subterranean formation so that the component is at least partially dissolved.
  • the present ivention provides a method comprising providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; and introducing the treatment fluid into a pipeline.
  • the present invention provides a method of treating a subterranean formation comprising providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into at least a portion of a subterranean formation.
  • the present invention provides a method copmrising providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and placing the treatment fluid into at least a portion of a subterranean formation at a pressure sufficient to create or enhance at least one fracture in the subterranean formation.
  • the present invention provides a method copmrising providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into a pipeline.
  • FIGURE 1 illustrates the rheological properties of a treatment fluid of the present invention.
  • FIGURE 2 illustrates the transmittance properties of clarified diutan and nonclarified diutan
  • FIGURE 3 illustrates the friction reduction properties of a treatment fluid of the present invention.
  • the present invention relates to methods and compositions for use in industrial, oilfield, and/or subterranean operations. More particularly, the present invention relates to treatment fluids comprising clarified diutan gelling agents, and their use in industrial, oilfield, geothermal, coal, coal bed methane, and/or subterranean operations.
  • compositions and methods of the present invention may be suitable for use in a variety of subterranean treatments, they may be particularly useful in treatments for subterranean formations comprising elevated temperatures, such as those above 200 0 F.
  • One of the many advantages of the treatment fluids of the present invention is that they may comprise decreased levels of residue as compared to traditional viscosified treatment fluids.
  • the treatment fluids of the present invention may also provide excellent particulate suspension and transport properties at temperatures above 200 0 F.
  • the treatment fluids of the present invention may also provide advantages over traditional viscosified treatment fluids in that they may provide enhanced filtration properties, better permeability regain and/or an increased rate of hydration.
  • the treatment fluids of the present invention generally comprise a base fluid and a gelling agent that comprises clarified diutan.
  • clarified diutan refers to a diutan that has improved turbidity and/or filtration properties as compared to nonclarified diutan.
  • suitable clarified diutans may have been treated with enzymes or the like to remove residual cellular structures, such as cell walls.
  • suitable clarified diutans may be produced from genetically modified or bioengineered strains of bacteria or other strains of bacteria that allow the clarified diutan to have improved functional properties such as filterability, turbidity, etc.
  • the clarified diutan may be modified by genetic engineering or bacteria selection or the result of chemical treatment or derivatization of a diutan.
  • An example of such a modification would be where a portion of the diutan is oxidized or hydrolyzed.
  • Suitable clarified diutan may also be present in a form that will only partially hydrate or will not hydrate at ambient temperature. This form of clarified diutan may be chemically modified, chemically coated, genetically modified, or produced from a new strain of bacteria.
  • diutan is a polysaccharide, which may be prepared by fermentation of a strain of sphingomonas.
  • Diutan may also be referred to as a polysaccharide designated S-657 and/or S-8 in some literature. Its structure has been elucidated as having a repeat unit of a hexasaccharide with a tetrasaccharide repeat unit in the backbone that comprises glucose and rhamnose units and a di-rhamnose side chain. It is believed to have thickening, suspending, and stabilizing properties in aqueous and/or nonaqueous solutions.
  • diutan gum structure may be found in an article by Diltz et al., "Location of O-acetyl Groups in S-657 Using the Reductive-Cleavage Method," CARBOHYDRATE RESEARCH, Vol. 331, p. 265-270 (2001), which is hereby incorporated by reference in its entirety. Details of preparing diutan gum may be found in U.S. Pat. No. 5,175,278, which is hereby incorporated by reference in its entirety.
  • a suitable source of diutan that may be chemically treated to obtain clarified diutan is "GEOVIS XT,” which is commercially available from Kelco Oil Field Group, Houston, Texas.
  • FDP-S848-07 Another suitable source of clarified diutan is "FDP-S848-07" and “FDP-S849-07,” both of which are available from Halliburton Energy Services, Duncan, Oklahoma.
  • Other examples of suitable sources of clarified diutan may include those disclosed in U.S. Patent Application Nos. 2006/0121578 and 2006/0199201, the relevant disclosures of which are herein incorporated by reference.
  • the gelling agent comprising clarified diutan may be provided in any form that is suitable for the particular treatment fluid and/or application of the present invention.
  • the gelling agent may be provided as a liquid, gel, suspension, and/or solid additive that is admixed or incorporated into a treatment fluid used in conjunction with the present invention.
  • the gelling agent may also be present in a solid particulate form of any size or shape. For example, larger sized particulates of spherical shape may be used, inter alia, to form perforation tunnel blocking particles, similar to perforation pack balls. Similarly, smaller sized particulates may be used, inter alia, as a fluid loss control material that may act to bridge natural fractures or other channels.
  • the gelling agent should be present in a treatment fluid of the present invention in an amount sufficient to impart the desired viscosity (e.g., sufficient viscosity to divert flow, reduce fluid loss, suspend particulates, provide friction reduction, etc.) to a treatment fluid. More specifically, in some embodiments, the amount of gelling agent used in the treatment fluids of the present invention may vary from about 0.25 pounds per 1000 gallons of treatment fluid ("lbs/Mgal") to about 200 Ibs/Mgal. In other embodiments, the amount of gelling agent included in the treatment fluids of the present invention may vary from about 30 Ibs/Mga ⁇ to about 80 lbs/Mgal.
  • a gelling agent in another embodiment, about 60 lbs/Mgal of a gelling agent is included in a treatment fluid of the present invention. It should be noted that in well bores comprising bottom hole temperatures of 200 0 F or more, 70 lbs/Mgal or more of the gelling agent may be beneficially used in a treatment fluid of the present invention. In embodiments in which the amount of clarified diutan approaches 200 lbs/Mgal, the clarified diutan may act to increase the viscosity of the treatment fluid so that the treatment fluid may be used as a diverting fluid, fluid loss pill to seal a formation, or as a chemical pig.
  • a treatment fluid of the present invention comprising a suitable clarified diutan at a 0.1% concentration in deionized water, in a 1 cm optical cell, has a transmittance at 600 nanometers ("nm") wavelength of at least about 65%.
  • the clarified diutan has a transmittance of at least about 75%.
  • the clarified diutan has a transmittance of at least about 85%.
  • any particular treatment fluid of the present invention may also vary depending on the addition of certain additives, the composition of the treatment fluid, the degree of hydration of the clarified diutan, the temperature, and the pH of the treatment fluid.
  • ordinary, unclarified diutan such as GEOVIS XT has a transmittance of about 58% or less.
  • a treatment fluid of the present invention comprising a suitable clarified diutan at a 0.1% concentration in deionized water, in a 1 cm optical cell, has a transmittance at 350 nanometers ("nm") wavelength of at least about 20%.
  • the clarified diutan has a transmittance of at least about 25%.
  • the clarified diutan has a transmittance of at least about 30%.
  • the clarified diutan has a transmittance of at least about 40%.
  • the clarified diutan has a transmittance of at least about 50%.
  • the clarified diutan has a transmittance of at least about 60%.
  • the clarified diutan has a transmittance of at least about 70%. In some embodiments, the clarified diutan has a transmittance of at least about 80%. In some embodiments, the clarified diutan has a transmittance of at least about 90%.
  • the transmittance of any particular treatment fluid of the present invention may also vary depending on the addition of certain additives, the composition of the treatment fluid, the degree of hydration of the clarified diutan, the temperature, and the pH of the treatment fluid.
  • ordinary, unclarified diutan such as GEOVIS XT has a transmittance of about 18% or less.
  • a treatment fluid of the present invention comprising a suitable clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) may have a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a ll cm Whatman #50 filter paper having a 2.7 ⁇ pore size.
  • a treatment fluid of the present invention may have a fluid loss greater than about 35 grams in 5 minutes.
  • a treatment fluid of the present invention may have a fluid loss greater than about 40 grams in 5 minutes.
  • a treatment fluid of the present invention may have a fluid loss greater than about 45 grams in 5 minutes.
  • ordinary, unclarified diutan such as GEOVIS XT has a fluid loss of about 25g or less.
  • a treatment fluid of the present invention comprising a suitable clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) may have a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 ⁇ pore size.
  • a treatment fluid of the present invention may have a fluid loss greater than about 150 grams in 5 minutes.
  • a treatment fluid of the present invention may have a fluid loss greater than about 155 grams in 5 minutes.
  • a treatment fluid of the present invention may have a fluid loss greater than about 160 grams in 5 minutes.
  • ordinary, unclarified diutan such as GEOVIS XT has a fluid loss of about 14Og or less.
  • a treatment fluid of the present invention comprising a suitable clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) may have a fluid loss greater than about 115 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 ⁇ pore size.
  • a treatment fluid of the present invention may have a fluid loss greater than about 120 grams in 2.5 minutes. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 130 grams in 2.5 minutes.
  • ordinary, unclarified diutan such as GEOVIS XT has a fluid loss of about 11Og or less. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 140 grams in 2.5 minutes.
  • the filtration rate of any particular treatment fluid of the present invention may also vary depending on the addition of certain additives, the composition of the treatment fluid, the degree of hydration of the clarified diutan, the temperature, and the pH of the treatment fluid.
  • Suitable base fluids for use in the present invention include aqueous base fluids and nonaqueous base fluids.
  • Suitable aqueous base fluids that may be used in the treatment fluids of the present invention may include fresh water, salt water, brine, seawater, or any other aqueous fluid that, preferably, does not adversely interact with the other components used in accordance with this invention or with the subterranean formation.
  • the aqueous base fluid preferably is present in the treatment fluids of the present invention in an amount sufficient to substantially hydrate the gelling agent to form a viscosified treatment fluid.
  • Suitable nonaqueous base fluids that may be used in the treatment fluids of the present invention may include glycerol, glycol, polyglycols, ethylene glycol, propylene glycol, and dipropylene gylcol methyl ether.
  • suitable nonaqueous base fluids that may be used in the present invention are disclosed in U.S. Patent No. 6,632,779, the relevant disclosure of which is herein incorporated by reference.
  • the base fluid may be present in the treatment fluids of the present invention in an amount in the range from about 5% to 99.99% by volume of the treatment fluid.
  • the base fluids suitable for use in the treatment fluids of the present invention may be foamed (e.g., a liquid that comprises a gas such as nitrogen or carbon dioxide).
  • foamed also refers to co-mingled fluids.
  • it may desirable that the base fluid is foamed to, inter alia, reduce the amount of base fluid that is required, e.g. in water sensitive subterranean formations, to reduce fluid loss to the subterranean formation, enhance flow back of fluids, and/or to provide enhanced proppant suspension.
  • the treatment fluids of the present invention are used for fluid diversion, it may be desirable that the treatment be foamed.
  • the gas may be present in a treatment fluid of the present invention in an amount in the range of from about 5% to about 98% by volume of the treatment fluid, and more preferably in the range of from about 20% to about 80%.
  • the amount of gas to incorporate into the fluid may be affected by factors including the viscosity of the fluid and wellhead pressures involved in a particular application.
  • a foamed fluid suitable for use with the present invention are those disclosed in U.S. Patent Application Serial No. 11/506,703, the relevant disclosure of which is herein incorporated by reference.
  • the treatment fluids of the present invention may also be used in the form of an emulsion.
  • An example of a suitable emulsion would comprise an aqueous base fluid comprising a clarified diutan gelling agent and a suitable hydrocarbon.
  • the emulsion may comprise approximately 30% of an aqueous base fluid and 70% of a suitable hydrocarbon.
  • the external phase of the emulsion would be aqueous.
  • Other benefits and advantages to using emulsions in the methods of the present invention will be evident to one of ordinary skill in the art.
  • the treatment fluids of the present invention may vary widely in density.
  • One of ordinary skill in the art with the benefit of this disclosure will recognize the particular density that is most appropriate for a particular application.
  • the density of the non-foamed treatment fluids of the present invention generally may approximate the density of water.
  • the density of the non-foamed treatment fluids of the present invention generally may range from about 8.3 pounds per gallon ("ppg") to about 20.5 ppg.
  • the density of any particular treatment fluid of the present invention may also vary depending on the addition of certain additives, including, but not limited to, proppant, gas, fluid loss control additives, alcohols, glycols, and/or hydrocarbons.
  • the desired density for a particular treatment fluid may depend on characteristics of the subterranean formation, including, inter alia, the hydrostatic pressure required to control the fluids of the subterranean formation during placement of the treatment fluids, and the hydrostatic pressure which will damage the subterranean formation. For example, if the treatment fluid remains in the well bore, the density of the treatment fluid may be adjusted to, inter alia, prevent the changing of position of a fluid relative to another fluid with a different density, thereby leaving the treatment fluid at the correct placement within the well bore.
  • the treatment fluid may comprise a brine.
  • Brines suitable for use in some embodiments of the present invention may include those that comprise monovalent, divalent, or trivalent cations.
  • Some divalent or trivalent cations such as magnesium, calcium, iron, and zirconium, may, in some concentrations and at some pH levels, cause undesirable crosslinking of a diutan polymer. If a water source is used which contains such divalent or trivalent cations in concentrations sufficiently high to be problematic, then such divalent or trivalent salts may be removed, either by a process such as reverse osmosis, or by raising the pH of the water in order to precipitate out such salts to lower the concentration of such salts in the water before the water is used.
  • chelating agent or chelant also refers to sequestering agents and the like. Suitable chelants include, but are not limited to, citric acid or sodium citrate. Other chelating agents also are suitable. Brines, where used, may be of any weight.
  • Suitable brines include calcium bromide brines, zinc bromide brines, calcium chloride brines, sodium chloride brines, sodium bromide brines, potassium bromide brines, potassium chloride brines, sodium nitrate brines, sodium formate brines, potassium formate brines, cesium formate brines, magnesium chloride brines, mixtures thereof, and the like.
  • the brine chosen should be compatible with the formation and should have a sufficient density to provide the appropriate degree of well control. Additional salts may be added to a water source, e.g., to provide a brine, and a resulting viscosified treatment fluid, having a desired density.
  • a preferred suitable brine is seawater.
  • the gelling agents of the present invention may be used successfully with seawater.
  • the gelling agents of the present invention may comprise an additional gelling agent if the use of the clarified diutan and the gelling agent produces a desirable result, e.g., a synergistic effect.
  • clarified diutan may be used in combination with other gelling agents so that the clarified duitan only imparts its viscosity once the treatment fluid has entered the formation to provide viscosity at elevated temperatures where other gelling agents may no longer provide adequate viscosity.
  • Suitable additional gelling agents may include polysaccharides and galactomannan gums. Depending on the application, one gelling agent may be more suitable than another.
  • the treatment fluids of the present invention also may optionally comprise salts, pH control additives, surfactants, breakers, bactericides, crosslinkers, fluid loss control additives, stabilizers, chelants, scale inhibitors, corrosion inhibitors, hydrate inhibitors, clay stabilizers, salt substitutes (such as trimethy] ammonium chloride), relative permeability modifiers (such as HPT- 1TM available from Halliburton Energy Services, Duncan, OK), sulfide scavengers, fibers, nanoparticles, combinations thereof, or the like.
  • salt substitutes such as trimethy] ammonium chloride
  • relative permeability modifiers such as HPT- 1TM available from Halliburton Energy Services, Duncan, OK
  • sulfide scavengers fibers, nanoparticles, combinations thereof, or the like.
  • Salts may optionally be included in the treatment fluids of the present invention for many purposes, including, for reasons related to compatibility of the treatment fluid with the formation and formation fluids.
  • a compatibility test may be performed to identify potential compatibility problems. From such tests, one of ordinary skill in the art with the benefit of this disclosure will be able to determine whether a salt should be included in a treatment fluid of the present invention.
  • Suitable salts include, but are not limited to, calcium chloride, sodium chloride, magnesium chloride, potassium chloride, sodium bromide, potassium bromide, ammonium chloride, sodium formate, potassium formate, cesium formate, mixtures thereof, and the like.
  • the amount of salt that should be added should be the amount necessary for formation compatibility, such as stability of clay minerals, taking into consideration the crystallization temperature of the brine, e.g., the temperature at which the salt precipitates from the brine as the temperature drops.
  • pH control additives which may optionally be included in the treatment fluids of the present invention are bases and/or acid compositions.
  • a pH control additive may be necessary to maintain the pH of the treatment fluid at a desired level, e.g., to improve the effectiveness of certain breakers and to reduce corrosion on any metal present in the well bore or formation, etc.
  • it may be beneficial to maintain the pH at neutral or above 7.
  • increasing the pH to 7 or above will give additional stability to the fluid at higher temperatures.
  • One of ordinary skill in the art with the benefit of this disclosure will be able to recognize a suitable pH for a particular application.
  • the pH control additive may be an acid composition.
  • suitable acid compositions may comprise an acid, an acid generating compound, and combinations thereof. Any known acid may be suitable for use with the treatment fluids of the present invention.
  • acids that may be suitable for use in the present invention include, but are not limited to organic acids (e.g., formic acids, acetic acids, carbonic acids, citric acids, glycolic acids, lactic acids, ethylenediaminetetraacetic acid (“EDTA”), hydroxyethyl ethylenediamine triacetic acid (“HEDTA”), and the like), inorganic acids (e.g., hydrochloric acid, hydrofluoric acid, phosphonic acid, p-toluenesulfonic acid, and the like), and combinations thereof.
  • organic acids e.g., formic acids, acetic acids, carbonic acids, citric acids, glycolic acids, lactic acids, ethylenediaminetetraacetic acid (“EDTA”), hydroxyethyl ethylenediamine
  • Examples of acid generating compounds that may be suitable for use in the present invention include, but are not limited to, esters, aliphatic polyesters, ortho esters, which may also be known as ortho ethers, poly (ortho esters), which may also be known as poly(ortho ethers), poly(lactides), poly(glycolides), poly( ⁇ -ca ⁇ rolactones), poly(hydroxybutyrates), ⁇ oly(anhydrides), or copolymers thereof.
  • copolymer as used herein is not limited to the combination of two polymers, but includes any combination of polymers, e.g., terpolymers and the like. Derivatives and combinations also may be suitable.
  • esters including, but not limited to, ethylene glycol monoformate, ethylene glycol diformate, diethylene glycol diformate, glyceryl monoformate, glyceryl diformate, glyceryl triformate, triethylene glycol diformate and formate esters of pentaerythritol.
  • esters including, but not limited to, ethylene glycol monoformate, ethylene glycol diformate, diethylene glycol diformate, glyceryl monoformate, glyceryl diformate, glyceryl triformate, triethylene glycol diformate and formate esters of pentaerythritol.
  • the pH control additive also may comprise a base to elevate the pH of the treatment fluid.
  • a base may be used to elevate the pH of the mixture to greater than or equal to about 7. Having the pH level at or above 7 may have a positive effect on a chosen breaker being used and may also inhibit the corrosion of any metals present in the well bore or formation, such as tubing, sand screens, etc.
  • having a pH greater than 7 may also impart greater stability to the viscosity of the treatment fluid, thereby enhancing the length of time that viscosity can be maintained. This could be beneficial in certain uses, such as in longer- term well control and in diverting.
  • Any known base that is compatible with the gelling agents of the present invention can be used in the treatment fluids of the present invention.
  • Suitable bases include, but are not limited to, sodium hydroxide, potassium carbonate, potassium hydroxide, sodium carbonate, and sodium bicarbonate.
  • An example of a suitable base is a solution of 25% sodium hydroxide commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradename "MO-67TM” pH control agent.
  • Another example of a suitable base solution is a solution of potassium carbonate commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradename "BA-40LTM” buffering agent.
  • the treatment fluid may optionally comprise a chelating agent.
  • the chelating agent may chelate any dissolved iron (or other divalent or trivalent cation) that may be present in the aqueous fluid. Such chelating may prevent such ions from crosslinking the gelling agent molecules. Such crosslinking may be problematic because, inter alia, it may cause filtration problems, injection problems, and/or cause regain permeability problems.
  • Any suitable chelating agent may be used with the present invention. Examples of suitable chelating agents include, but are not limited to, an anhydrous form of citric acid, commercially available under the tradename "Fe-2TM” Iron Sequestering Agent from Halliburton Energy Services, Inc., of Duncan, Oklahoma.
  • a suitable chelating agent is a solution of citric acid dissolved in water, commercially available under the tradename "Fe-2ATM” buffering agent from Halliburton Energy Services, Inc., of Duncan, Oklahoma.
  • Other chelating agents that may be suitable for use with the present invention include, inter alia, nitrilotriacetic acid (“NTA”), any fo ⁇ n of ethylene diamine tetracetic acid (“EDTA”), hydroxyethylethylenediaminetriacetic acid (“HEDTA”), dicarboxymethyl glutamic acid tetrasodium salt (“GLDA”), diethylenetriaminepentaacetic acid (“DTPA”), propylenediaminetetraacetic acid (“PDTA”), ethylenediaminedi(o- hydroxyphenylacetic) acid (“EDDHA”), glucoheptonic acid, gluconic acid, sodium citrate, phosphonic acid, salts thereof, and the like.
  • NTA nitrilotriacetic acid
  • the chelating agent may be a sodium or potassium salt.
  • the chelating agent may be present in an amount sufficient to prevent crosslinking of the gelling agent molecules by any free iron (or any other divalent or trivalent cation) that may be present.
  • the chelating agent may be present in an amount of from about 0.02% to about 50.0% by weight of the treatment fluid.
  • the chelating agent is present in an amount in the range of from about 0.02% to about 2.0% by weight of the treatment fluid.
  • the treatment fluids of the present invention may include surfactants, e.g., to improve the compatibility of the treatment fluids of the present invention with other fluids (like any formation fluids) that may be present in the well bore.
  • surfactants e.g., to improve the compatibility of the treatment fluids of the present invention with other fluids (like any formation fluids) that may be present in the well bore.
  • surfactants may be used in a liquid or powder form. Where used, the surfactants may be present in the treatment fluid in an amount sufficient to prevent incompatibility with formation fluids, other treatment fluids, or well bore fluids.
  • the surfactants are generally present in an amount in the range of from about 0.01% to about 5.0% by volume of the treatment fluid. In one embodiment, the liquid surfactants are present in an amount in the range of from about 0.1% to about 2.0% by volume of the treatment fluid. In embodiments where powdered surfactants are used, the surfactants may be present in an amount in the range of from about 0.001% to about 0.5% by weight of the treatment fluid.
  • Suitable surfactants are non-emulsifiers commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradenames "LOSURF-259TM” nonionic nonemulsif ⁇ er, "LOSURP-300TM” nonionic surfactant, “LOSURF-357TM” nonionic surfactant, and "LOSURP- 400TM” surfactant.
  • Another example of a suitable surfactant is a non-emulsifier commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradename "NEA-96MTM” Surfactant.
  • the surfactant may be a viscoelastic surfactant.
  • These viscoelastic surfactants may be cationic, anionic, nonionic, amphoteric, or zwitterionic in nature.
  • the viscoelastic surfactants may comprise any number of different compounds, including methyl ester sulfonates (e.g., as described in U.S. Patent Application Nos. 2006/0180310, 2006/0180309, 2006/0183646 and U.S. Patent No. 7,159,659, the relevant disclosures of which are incoiporated herein by reference), hydrolyzed keratin (e.g., as described in United States Patent No.
  • sulfosuccinates taurates, amine oxides, ethoxylated amides, alkoxylated fatty acids, alkoxylated alcohols (e.g., lauryl alcohol ethoxylate, ethoxylated nonyl phenol), ethoxylated fatty amines, ethoxylated alkyl amines (e.g., cocoalkylamine ethoxylate), betaines, modified betaines, alkylamidobetaines (e.g., cocoamidopropyl betaine), quaternary ammonium compounds (e.g., trimethyltallowammonium chloride, trimethylcocoammonium chloride), derivatives thereof, and combinations thereof.
  • alkoxylated alcohols e.g., lauryl alcohol ethoxylate, ethoxylated nonyl phenol
  • ethoxylated fatty amines ethoxylated alkyl amines (e.g.
  • surfactants such as HY-CLEAN (HC-2)TM surface-active suspending agent or AQF-2TM additive, both commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, may be used.
  • foaming agents that may be utilized to foam and stabilize the acidic treatment fluids of this invention include, but are not limited to, betaines, amine oxides, methyl ester sulfonates, alkylamidobetaines such as cocoamidopropyl betaine, alpha-olefm sulfonate, trimethyltallowammonium chloride, C8 to C22 alkylethoxylate sulfate and trimethylcocoammonium chloride.
  • Suitable surfactants that may or may not be foamers in a particular application that are available from Halliburton Energy Services include: “19N,” “G-sperse Dispersant,” “Howco-SudsTM” foaming agent, and “A-SperseTM” dispersing aid for acid additives.
  • suitable foaming agents and foam stabilizing agents may be included as well, which will be known to those skilled in the art with the benefit of this disclosure.
  • emulsifying surfactant it may be desirable to emulsify the treatment fluid with a hydrocarbon, forming a aqueous phase external emulsion.
  • an emulsifying surfactant would be used.
  • a suitable emulsifying surfactant includes a nonionic surfactant such as a sorbitan ester. SEM-7TM Emulsifier, available from Halliburton Energy Services in Duncan, Oklahoma is an example of another suitable surfactant. If a surfactant is used, generally an amount from about 0.1% to about 3% based on volume is sufficient.
  • the emulsion can be mixed and then pumped. In other embodiments, the components can be pumped and then mixed down hole.
  • microemulsion additives may optionally be included in the treatment fluids of the present invention.
  • suitable microemulsion additives include, but are not limited to, "Pen-88MTM” surfactant, “Pen-88HTTM” surfactant, "SSO-21E” surfactant, “SSO-21MWTM” surfactant, GasPerm 1000TM Microemulsion Surfactant/Solvent Additive, which are all commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma.
  • microemulsion additives are MA-845 additive and MA-844 additive, commercially available from CESI Chemical of Duncan, Oklahoma; ShaleSurf 1000 additive, commercially available from Frac Tech Services of Aledo, Texas; and those disclosed in U.S. Patent App. No. 2003/0166472, the relevant disclosure of which is incorporated by reference.
  • the treatment fluids of the present invention may contain bactericides, inter alia, to protect both the subterranean formation as well as the treatment fluid from attack by bacteria. Such attacks may be problematic because they may lower the viscosity of the treatment fluid, resulting in poorer performance, such as poorer sand suspension properties, for example. Any bactericides known in the art are suitable. An artisan of ordinary skill with the benefit of this disclosure will be able to identify a suitable bactericide and the proper concentration of such bactericide for a given application. Where used, such bactericides are present in an amount sufficient to destroy all bacteria that may be present.
  • bactericides examples include, but are not limited to, a 2,2-dibromo-3-nitrilopropionamide, commercially available under the tradename "BE-3STM” biocide from Halliburton Energy Services, Inc., of Duncan, Oklahoma, and a 2-bromo-2-nitro- 1 ,3 -propanediol commercially available under the tradename "BE-6TM” biocide from Halliburton Energy Services, Inc., of Duncan, Oklahoma.
  • the bactericides are present in the treatment fluid in an amount in the range of from about 0.001% to about 1.0% by weight of the treatment fluid.
  • they may be added to the treatment fluid before the gelling agent is added.
  • the treatment fluids of the present invention optionally may comprise a suitable crosslinker to crosslink the clarified diutan gelling agent in the treatment fluid.
  • Crosslinking may be desirable at higher temperatures and/or when the sand suspension properties of a particular fluid of the present invention may need to be altered for a particular purpose.
  • crosslinking may be beneficial when using the treatment fluids of the present invention to seal formation zones from loss of fluid from the well bore or when used as a pig for pipeline cleaning.
  • Suitable crosslinkers include, but are not limited to, boron derivatives and salts thereof; potassium derivatives, including but not limited to, potassium periodate; ferric iron complexes and compounds; magnesium complexes and compounds; calcium complexes and compounds, barium complexes and compounds, copper complexes and compounds, aluminum complexes and compounds, cadmium complexes and compounds, zinc complexes and compounds, mercury complexes and compounds, nickel complexes and compounds, lead complexes and compounds, chrome (chromium) complexes and compounds, zirconium complexes and compounds; antimony complexes and compounds; and titanium complexes and compounds.
  • potassium derivatives including but not limited to, potassium periodate
  • ferric iron complexes and compounds magnesium complexes and compounds
  • calcium complexes and compounds barium complexes and compounds, copper complexes and compounds, aluminum complexes and compounds, cadmium complexes and compounds, zinc complexes and compounds, mercury complexes and compounds, nickel complexes and compounds, lead complexes and
  • the treatment fluids of the present invention also may comprise breakers capable of reducing the viscosity of the treatment fluid at a desired time.
  • suitable breakers for treatment fluids of the present invention include, but are not limited to, sodium chlorites, hypochlorites, perborate, persulfates, peroxides, including organic peroxides.
  • Other suitable breakers include, but are not limited to, suitable acids and peroxide breakers, delinkers, as well as enzymes that may be effective in breaking diutan.
  • Another example of suitable breakers are those in U.S. Patent Application Serial No. 11/502,656, the relevant disclosure of which is herein incorporated by reference.
  • peroxide breakers include tert-butyl hydroperoxide and tert-amyl hydroperoxide.
  • a breaker may be included in a treatment fluid of the present invention in an amount and form sufficient to achieve the desired viscosity reduction at a desired time.
  • the breaker may be formulated to provide a delayed break, if desired.
  • a suitable breaker may be encapsulated if desired. Suitable encapsulation methods are known to those skilled in the art.
  • One suitable encapsulation method that may be used involves coating the chosen breakers with a material that will degrade when downhole so as to release the breaker when desired. Resins that may be suitable include, but are not limited to, polymeric materials that will degrade when downhole.
  • degrade refers to both the two relatively extreme cases of degradation that the degradable material may undergo, i.e., heterogeneous (or bulk erosion) and homogeneous (or surface erosion), and any stage of degradation in between these two.
  • This degradation can be a result of, inter alia, a chemical or thermal reaction or a reaction induced by radiation.
  • degradable materials include, but are not limited to, polysaccharides such as dextran or cellulose; chitins; chitosans; proteins; aliphatic polyesters; poly(lactides); poly(glycolides); poly( ⁇ -caprolactones); poly(hydroxybutyrates); poly(anhydrides); aliphatic polycarbonates; orthoesters, poly(orthoesters); poly(amino acids); poly(ethylene oxides); and polyphosphazenes.
  • a breaker should be included in a treatment fluid of the present invention in an amount sufficient to facilitate the desired reduction in viscosity in a treatment fluid. For instance, peroxide concentrations that may be used vary from about 0.1 to about 30 gallons of peroxide per 1000 gallons of the treatment fluid.
  • a treatment fluid of the present invention may comprise an activator or a retarder, inter alia, to optimize the break rate provided by the breaker.
  • Any known activator or retarder that is compatible with the particular breaker used is suitable for use in the present invention.
  • suitable activators include, but are not limited to, acid generating materials, chelated iron, copper, cobalt, and reducing sugars.
  • suitable retarders include sodium thiosulfate, methanol, and diethylene triamine.
  • the sodium thiosulfate may be used in a range of from about 1 to about 100 lbs/Mgal of treatment fluid. A preferred range may be from about 5 to about 20 lbs/Mgal.
  • An artisan of ordinary skill with the benefit of this disclosure will be able to identify a suitable activator or retarder and the proper concentration of such activator or retarder for a given application.
  • the treatment fluids of the present invention also may comprise suitable fluid loss control agents.
  • Such fluid loss control agents may be particularly useful when a treatment fluid of the present invention is being used in a fracturing application or in a fluid used to seal a formation from invasion of fluid from the well bore.
  • Any fluid loss agent that is compatible with the treatment fluids of the present invention is suitable for use in the present invention. Examples include, but are not limited to, starches, silica flour, gas bubbles (energized fluid or foam), benzoic acid, soaps, resin particulates, relative permeability modifiers, degradable gel particulates, diesel dispersed in fluid, and other immiscible fluids.
  • Another example of a suitable fluid loss control additive is one that comprises a degradable material.
  • degradable materials include polysaccharides such as dextran or cellulose; chitins; chitosans; proteins; aliphatic polyesters; poly(lactides); poly(glycolides); poly(glycolide-co-lactides); poly( ⁇ -caprolactones); poly(3-hydroxybutyrates); poly(3-hydroxybutyrate-co-hydroxyvalerates); poly(anhydrides); aliphatic poly (carbonates); poly(orthoesters); poly(amino acids); poly(ethylene oxides); poly(phosphazenes); derivatives thereof; or combinations thereof.
  • a fluid loss additive should be added to a treatment fluid of the present invention in an amount necessary to give the desired fluid loss control.
  • a fluid loss additive may be included in an amount of about 5 to about 2000 Ibs/Mgal of the treatment fluid. In some embodiments, the fluid loss additive may be included in an amount from about 10 to about 50 Ibs/Mgal of the treatment fluid. For some liquid additives like diesel, these may be included in an amount from about 0.01% to about 20% by volume; in some embodiments, these may be included in an amount from about 1.0% to about 10% by volume.
  • a stabilizer may optionally be included in the treatment fluids of the present invention. It may be particularly advantageous to include a stabilizer if a chosen treatment fluid is experiencing a viscosity degradation.
  • a stabilizer might be beneficial is where the BHT of the well bore is sufficient by itself to break the treatment fluid without the use of a breaker.
  • Suitable stabilizers include, but are not limited to, sodium thiosulfate, methanol, and salts such as formate salts and potassium chloride.
  • Another example of a suitable stabilizer includes surfactants, such as those in U.S. Patent Application Serial No. 11/418,617, the relevant disclosure of which is herein incorporated by reference.
  • Such stabilizers may be useful when the treatment fluids of the present invention are utilized in a subterranean formation having a temperature above about 200 0 F.
  • a stabilizer may be added in an amount of from about 1 to about 50 Ibs/Mgal of treatment fluid. In other embodiments, a stabilizer may be included in an amount of from about 5 to about 20 Ibs/Mgal of treatment fluid. In certain embodiments where the stabilizer chosen is a salt, the stabilizer may be included in an amount of from about 5 Ibs/Mgal to about saturation of the treatment fluid. In certain embodiments where the stabilizer chosen is a surfactant, the stabilizer may be included in an amount of from about 0.001% to about 5.0% of the treatment fluid.
  • Scale inhibitors may be added to the treatment fluids of the present invention, for example, when a treatment fluid of the present invention is not particularly compatible with the formation waters in the formation in which it is being used.
  • This may include water soluble organic molecules with carboxylic acid, aspartic acid, maleic acids, sulphonic acids, phosphonic acid and phosphate esters groups including copolymers, ter- polymers, grafted copolymers, and derivatives thereof.
  • Examples of such compounds include aliphatic phosphonic acids such as diethylene triamine penta (methylene phosphonate) and polymeric species such as polyvinylsulphonate.
  • the scale inhibitor may be in the form of the free acid but is preferably in the form of mono and polyvalent cation salts such as Na, K, Al, Fe, Ca, Mg, N ⁇ 4 .
  • Any scale inhibitor that is compatible with the treatment fluid in which it will be used in suitable for use in the present invention is Scalechek LP-55TM scale inhibitor commercially available from Halliburton Energy Services in Duncan, Oklahoma.
  • Another example of a suitable scale inhibitor is LP-65TM scale inhibitor commercially available from Halliburton Energy Services in Duncan, Oklahoma.
  • a scale inhibitor should be included in an amount effective to inhibit scale formation. Suitable amounts of scale inhibitors that may be included in the treatment fluids of the present invention may range from about 0.05 to 100 gallons per about 1000 gallons of the treatment fluid.
  • any particulates such as proppant and/or gravel that are commonly used in subterranean operations may be used in the present invention (e.g., sand, gravel, bauxite, ceramic materials, glass materials, polymer materials, wood, plant and vegetable matter, nut hulls, walnut hulls, cotton seed hulls, cement, fly ash, fibrous materials, composite particulates, hollow spheres and/or porous proppant).
  • sand, gravel, bauxite ceramic materials, glass materials, polymer materials, wood, plant and vegetable matter, nut hulls, walnut hulls, cotton seed hulls, cement, fly ash, fibrous materials, composite particulates, hollow spheres and/or porous proppant.
  • the term "particulate,” as used in this disclosure includes all known shapes of materials including substantially spherical materials, oblong, ellipsoid, rod-like, polygonal materials (such as cubic materials), mixtures thereof, and the like.
  • resin and/or tackifying agent coated particulates may be suitable for use in the treatment fluids of the present invention.
  • proppants that have been chemically treated or coated may also be used.
  • coated does not imply any particular degree of coverage of the proppant particulates with the resin and/or tackifying agent. Examples of tackifying agents suitable for coating particulates are described in U.S. Patent Nos. 5,853,048; 5,833,000; 5,582,249; 5,775,425; 5,787,986, 7,131,491 the relevant disclosures of which are herein incorporated by reference.
  • tackifying agent An example of a suitable commercially available tackifying agent is the "SAND WEDGE” product sold by Halliburton Energy Services, Inc. of Duncan, Oklahoma. Examples of resins suitable for coating particulates are described in U.S. Patent Nos. 6,668,926; 6,729,404; and 6,962,200. An example of a suitable commercially available resin is the "EXPEDITE” product sold by Halliburton Energy Services, Inc. of Duncan, Oklahoma. [0060]
  • the treatment fluids of the present may be provided and introduced into the subterranean formation in certain embodiments of the present invention by any means known in the art.
  • the treatment fluid may be prepared at the job site, prepared at a plant or facility prior to use, or certain components of the treatment fluid (e.g., the base fluid and the gelling agent) may be pre-mixed prior to use and then transported to the job site. Certain components of the treatment fluid may be provided as a "dry mix" to be combined with the base fluid and/or other components prior to or during introducing the treatment fluid into the subterranean formation.
  • certain components of the treatment fluid may be provided as a "dry mix" to be combined with the base fluid and/or other components prior to or during introducing the treatment fluid into the subterranean formation.
  • the preparation of these treatment fluids of the present invention may be done at the job site in a method characterized as being performed "on the fly."
  • the term "on-the-fly” is used herein to include methods of combining two or more components wherein a flowing stream of one element is continuously introduced into flowing stream of another component so that the streams are combined and mixed while continuing to flow as a single stream as part of the on-going treatment. Such mixing can also be described as "real-time” mixing.
  • the gelling agent comprising clarified diutan may be mixed into the base fluid on the fly.
  • the treatment fluid may be introduced into the subterranean formation by pumping the treatment fluid into a well bore that penetrates a portion of the subterranean formation.
  • the treatment fluid may be introduced into the subterranean formation at or above a pressure sufficient to create or enhance one or more fractures in a portion of the subterranean formation.
  • the treatment fluids of the present invention may be placed in a subterranean formation utilizing a hydrajet tool.
  • the hydrajet tool may be capable of increasing or modifying the velocity and/or direction of the flow of a fluid into a subterranean formation from the velocity and/or direction of the flow of that fluid down a well bore.
  • One of the potential advantages of using a hydrajet tool is that a fluid may be introduced adjacent to and localized to specific areas of interest along the well bore without the use of mechanical or chemical barriers.
  • the fluid(s) introduced through the hydrajet tool are introduced at a pressure sufficient to result in the creation of at least one new fracture in the formation.
  • a hydrajetting operation carried out at an elevated pressure a hydrajetting tool having at least one fluid jet forming nozzle is positioned adjacent to a formation to be fractured, and fluid is then jetted through the nozzle against the formation at a pressure sufficient to form a cavity, or slot therein to fracture the formation by stagnation pressure in the cavity.
  • the jetted fluids would have to flow out of the slot in a direction generally opposite to the direction of the incoming jetted fluid, they are trapped in the slot and create a relatively high stagnation pressure at the tip of a cavity.
  • This high stagnation pressure may cause a micro-fracture to be formed that extends a short distance into the formation. That micro-fracture may be further extended by pumping a fluid into the well bore to raise the ambient fluid pressure exerted on the formation while the formation is being hydrajetted.
  • Such a fluid in the well bore will flow into the slot and fracture produced by the fluid jet and, if introduced into the well bore at a sufficient rate and pressure, may be used to extend the fracture an additional distance from the well bore into the formation.
  • the methods and treatment fluids of the present invention may be used during or in preparation for any subterranean operation wherein a fluid may be used.
  • Suitable subterranean operations may include, but are not limited to, drilling operations, hydraulic fracturing treatments, fracturing treatments such as those disclosed in U.S. Patent Application Serial No. 11/506,703, the relevant disclosure of which is hereby incorporated by reference, sand control treatments (e.g., gravel packing), acidizing treatments (e.g., matrix acidizing, fracture acidizing, removal of filter cakes and fluid loss pills), "frac-pack" treatments, well bore clean-out treatments, and other suitable operations where a treatment fluid of the present invention may be useful.
  • the treatment fluids of the present invention may also be used in conjunction with a remedial treatment utilizing vibrational waves, an example of which is dislcosed in U.S. Patent Application No. 2006/0131012, the relevnat disclosure of which is herein incorporated by reference.
  • the treatment fluids of the present invention may also be used to reduce friction, as a spacer fluid, insulation fluid, as a diverter, as a fluid loss pill, as part of a drilling fluid, as a chemical pig in a well bore, or as a chemical pig in a pipeline.
  • the treatment fluid may also comprise a cement slurry.
  • the present invention provides a method that comprises: providing a treatment fluid that comprises a base fluid and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into a subterranean formation.
  • placing the treatment fluid into the subterranean formation comprises placing the treatment fluid into a well bore penetrating the subterranean formation.
  • the treatment fluid may be introduced into the subterranean formation at or above a pressure sufficient to create or enhance at least one fracture in the subterranean formation.
  • the treatment fluid may comprise a plurality of gravel particulates, and the methods may further comprise depositing at least a portion of those particulates in a desired area in a well bore, e.g., to form a gravel pack, provide some degree of sand control in the subterranean formation, and/or prevent the flow of particulates from an unconsolidated portion of the subterranean formation (e.g., a propped fracture) into a well bore.
  • an unconsolidated portion of the subterranean formation e.g., a propped fracture
  • the present invention provides a method that comprises: providing a treatment fluid that comprises a base fluid, an acid composition and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into a subterranean formation.
  • these treatment fluids may be introduced into the subterranean formation at or above a pressure sufficient to create or enhance at least one fracture in the subterranean formation.
  • the comparative sample, Sample 3 was prepared by blending 2 grams of "GEOVIS XT," a non- clarified diutan, in 200 milliliters (“mL") of 15% hydrochloric acid in a Waring Blender for approximately 10 minutes, with a 10 minute pressure test in the Grace M56OO prior to conducting the measurements. Once prepared, the samples were placed in the cup of a Grace M5600 viscometer to determine the viscosity of the sample at several temperatures. The samples were subjected to a shear rate of about 100 sec "1 using a Bl bob with a shear sweep of 40, 100, and 170 sec "1 . The sample temperatures were increased from room temperature to approximately 300 0 F while the viscosities of the samples were measured. The results of this test are displayed in Tables I 5 2, and 3 for Samples 1, 2, and 3, respectively.
  • FIGURE 1 is a plot of the calculated viscosity (cP) of Sample 1 "FDP- S848-07” and Sample 3 ("GEOVIS XT”) at 100 sec '1 vs. temperature ( 0 F).
  • Sample 6 contained 0.2 grams of "GEOVIS XT,” a nonclarified diutan available from Kelco Oil Field Group, in 200 mL of deionized water.
  • the deionized water was placed in a Waring blender and the diutan powder was slowly incorporated into the water over approximately ten seconds at 800 to 1,000 revolutions per minute (“rpm")-
  • rpm revolutions per minute
  • Each sample was then mixed in the blender for approximately one hour at 1,500 rpm.
  • each sample was then centrifuged at room temperature at 1,000 rpm on a bench top centrifuge for approximately fifteen minutes to remove gas bubbles before measuring the transmittance.
  • the transmittance measurement of each sample was then obtained by placing the sample in a UV- Visible spectrophotometer (e.g.
  • FIGURE 2 illustrates the transmittance properties of clarified diutan and nonclarified diutan.
  • the FR Meter was a closed loop pipeline apparatus designed to measure the pressure drop across an 8-foot segment of a 13- foot smooth Hastelloy C pipe.
  • the 8-foot test segment of the 13-foot pipe is positioned to significantly minimize pipe entrance and exit effects on the friction pressure measurement.
  • the smooth Hastelloy C pipe had an inner diameter of 0.554 inches.
  • the FR Meter included a storage/mixing tank connected to a fixed speed progressive cavity pump which pumped the test fluid through a magnetic flow meter then through the test pipes and a return line to the storage/mixing tank.
  • ⁇ P water is the calculated pressure drop for the water
  • p density of water
  • V is the velocity
  • L is length
  • g c is the gravitational constant
  • D h is the pipe diameter
  • is pipe roughness
  • d is the pipe diameter
  • Nn e is the Reynolds Number (Shacham, M., Isr. Chem. Eng., 8, 7E (1976)).
  • is zero.
  • AP water is the calculated pressure drop for the water and ⁇ F meaS wed is the measured pressure drop after introduction of the solution containing FDP-S848-O7.
  • every range of values (of the form, "from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b") disclosed herein is to be understood as referring to the power set (the set of all subsets) of the respective range of values, and set forth every range encompassed within the broader range of values.
  • the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee.

Abstract

Treatment fluids are provided that include a treatment fluid comprising a base fluid and a gelling agent that comprises clarified diutan. In some embodiments, the treatment fluid is a subterranean treatment fluid. In some embodiments, the treatment fluid is a subterranean treatment fluid comprising a base fluid, a gelling agent that comprises clarified diutan, and at least a plurality of particulates. Methods are provided that include a method comprising providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; and introducing the acidic treatment fluid into at least a portion of a subterranean formation. In some embodiments, the acidic treatment fluid may be allowed to interact with a component of the subterranean formation so that the component is at least partially dissolved. In some embodiments, the acidic treatment fluid may be introduced into a pipeline.

Description

TREATMENT FLUIDS COMPRISING DIUTAN AND ASSOCIATED METHODS
BACKGROUND
[0001] The present invention relates to methods and compositions for use in industrial, oilfield, and/or subterranean operations. More particularly, the present invention relates to treatment fluids comprising clarified diutan gelling agents, and their use in industrial, oilfield, geothermal, coal, coal bed methane, and/or subterranean operations.
[0002] Treatment fluids may be used in a variety of subterranean treatments, including, but not limited to, stimulation treatments, damage removal, formation isolation, wellbore cleanout, scale removal, scale control, drilling operations, cementing, conformance treatments, and sand control treatments. Treatment fluids may also be used in a variety of pipeline treatments. As used herein, the term "treatment," or "treating," refers to any operation that uses a fluid in conjunction with a desired function and/or for a desired purpose. The term "treatment," or "treating," does not imply any particular action by the fluid or any particular component thereof.
[0003] One common production stimulation operation that employs a treatment fluid is hydraulic fracturing. Hydraulic fracturing operations generally involve pumping a treatment fluid (e.g., a fracturing fluid) into a well bore that penetrates a subterranean formation at a sufficient hydraulic pressure to create or enhance one or more cracks, or "fractures," in the subterranean formation. "Enhancing" one or more fractures in a subterranean formation, as that term is used herein, is defined to include the extension or enlargement of one or more natural or previously created fractures in the subterranean formation. The treatment fluid may comprise particulates^ often referred" to as "proppant "particulates," that are deposited in the fractures. The proppant particulates, inter alia, may prevent the fractures from fully closing upon the release of hydraulic pressure, forming conductive channels through which fluids may flow to the well bore. The proppant particulates also may be coated with certain types of materials, including resins, tackifying agents, and the like, among other purposes, to enhance conductivity (e.g., fluid flow) through the fractures in which they reside. Once at least one fracture is created and the proppant particulates are substantially in place, the treatment fluid may be "broken" (i.e., the viscosity of the fluid is reduced), and the treatment fluid may be recovered from the formation.
[0004] Other common production stimulation operations that employ treatment fluids are acidizing operations. Where the subterranean formation comprises acid-soluble components, such as those present in carbonate and sandstone formations, stimulation and/or damage removal is often achieved by contacting the formation with a treatment fluid that comprises an acid. For example, where hydrochloric acid contacts and reacts with calcium carbonate in a formation, the calcium carbonate is consumed to produce water, carbon dioxide, and calcium chloride. After acidization is completed, the water and salts dissolved therein may be recovered by producing them to the surface (e.g., "flowing back" the well), leaving a desirable amount of voids (e.g., wormholes) within the formation, which may enhance the formation's permeability and/or increase the rate at which hydrocarbons subsequently may be produced from the formation. One method of acidizing known as "fracture acidizing" comprises injecting a treatment fluid that comprises an acid into the formation at a pressure sufficient to create or enhance one or more fractures within the subterranean formation. Another method of acidizing known as "matrix acidizing" comprises injecting a treatment fluid that comprises an acid into the formation at a pressure below that which would create or enhance one or more fractures within the subterranean formation.
[0005] Treatment fluids are also utilized in sand control treatments, such as gravel packing. In "gravel -packing" treatments, a treatment fluid suspends particulates (commonly referred to as "gravel particulates"), and deposits at least a portion of those particulates in a desired area in a well bore, e.g., near unconsolidated or weakly consolidated formation zones, to form a "gravel pack," which is a grouping of particulates that are packed sufficiently close together so as to prevent the passage of certain materials through the gravel pack. This "gravel pack" may, inter alia, enhance sand control in the subterranean formation and/or prevent the flow of particulates from an unconsolidated portion of the subterranean formation (e.g., a propped fracture) into a well bore. One common type of gravel-packing operation involves placing a sand control screen in the well bore and packing the annulus between the screen and the well bore with the gravel particulates of a specific size designed to prevent the passage of formation sand. The gravel particulates act, inter alia, to prevent the formation sand from occluding the screen or migrating with the produced hydrocarbons, and the screen acts, inter alia, to prevent the particulates from entering the well bore. The gravel particulates also may be coated with certain types of materials, including resins, tackifying agents, and the like, among other purposes, to enhance conductivity (e.g., fluid flow) through the gravel pack in which they reside. Once the gravel pack is substantially in place, the viscosity of the treatment fluid may be reduced to allow it to be recovered. In some situations, fracturing and gravel-packing treatments are combined into a single treatment (commonly referred to as "FracPac™" operations). In such "frac pack" operations, the treatments are generally completed with a gravel pack screen assembly in place with the hydraulic fracturing treatment being pumped through the annular space between the casing and screen. In this situation, the hydraulic fracturing treatment ends in a screen-out condition, creating an annular gravel pack between the screen and casing. In other cases, the fracturing treatment may be performed prior to installing the screen and placing a gravel pack.
[0006] Maintaining sufficient viscosity in the treatment fluids used in these operations is important for a number of reasons. Maintaining sufficient viscosity is important in fracturing and sand control treatments for particulate transport and/or to create or enhance fracture width. Also, maintaining sufficient viscosity may be important in acid treatments, in friction reduction and to control and/or reduce fluid loss into the formation. Moreover, a treatment fluid of a sufficient viscosity may be used to divert the flow of fluids present within a subterranean foπnation (e.g., formation fluids, other treatment fluids) to other portions of the formation, for example, by invading the higher permeability portions of the formation with a fluid that has high viscosity at low shear rates. To further increase the viscosity of a treatment fluid, often the molecules of the gelling agent are "crosslinked" with the use of a crosslinking agent. Conventional crosslinking agents usually comprise a metal complex or compound that interacts with at least two polymer molecules to form a "crosslink" between them.
[0007] To provide the desired viscosity, polymeric gelling agents commonly are added to the treatment fluids. Examples of commonly used polymeric gelling agents include, but are not limited to, biopolymers, polysaccharides such as guar gums and derivatives thereof, cellulose derivatives, synthetic polymers, and the like. These gelling agents, when hydrated and at a sufficient concentration, are capable of forming a viscous solution. When used to make an aqueous-based viscosified treatment fluid, a gelling agent is combined with an aqueous fluid and the soluble portions of the gelling agent are dissolved in the aqueous fluid, thereby increasing the viscosity of the fluid. However, the insoluble portions of the gelling agents (referred to herein as "residue"), such as proteins, cellulose and fibers, remain in the aqueous fluid and enter the pores of the subterranean zones being treated as well as gravel packs and proppant packs in the zones. The presence of this residue may impair the producing capabilities and/or the permeability of the subterranean formation and is therefore undesirable.
[0008] In addition, although certain viscosified treatment fluids may be desirable because of their advantageous properties, such as sand transport properties, long-lasting viscosity, desirable sheer thinning characteristics, and efficient breaking properties, it may not be practicable to use such gelling agents if the aqueous base fluid is a brine. The term "brine" as used herein refers to various salts and salt mixtures dissolved in aqueous fluids. For example, when a brine is used in conjunction with certain gelling agents, the insoluble portions of the gelling agents may agglomerate in the presence of certain salts, such as potassium chloride, thereby making it difficult to achieve the desired viscosity. Furthermore, the agglomeration of insoluble portions of the gelling agent may also prevent effective filtration of the viscosified fluid.
SUMMARY
[0009] The present invention relates to methods and compositions for use in industrial, oilfield, and/or subterranean operations. More particularly, the present invention relates to treatment fluids comprising clarified diutan gelling agents, and their use in industrial, oilfield, geothermal, coal, coal bed methane, and/or subterranean operations.
[0010] In one embodiment, the present invention provides a treatment fluid comprising a base fluid and a gelling agent that comprises clarified diutan.
[0011] In another embodiment, the present invention provides a subterranean treatment fluid comprising a base fluid, a gelling agent that comprises clarified diutan, and an acid composition.
[0012] In another embodiment, the present invention prvides a subterranean treatment fluid comprising a base fluid, a gelling agent that comprises clarified diutan, and at least a plurality of particulates.
[0013] In another embodiment, the present invention provides a method comprising providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; and introducing the acidic treatment fluid into at least a portion of a subterranean formation.
[0014] In another embodiment, the present invention provides a method comprising providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; contacting a portion of a subterranean formation with the acidic treatment fluid; and allowing the acidic treatment fluid to interact with a component of the subterranean formation so that the component is at least partially dissolved.
[0015] In another embodiment, the present ivention provides a method comprising providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; and introducing the treatment fluid into a pipeline.
[0016] In another embodiment, the present invention provides a method of treating a subterranean formation comprising providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into at least a portion of a subterranean formation.
[0017] In another embodiment, the present invention provides a method copmrising providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and placing the treatment fluid into at least a portion of a subterranean formation at a pressure sufficient to create or enhance at least one fracture in the subterranean formation.
[0018] In another embodiment, the present invention provides a method copmrising providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into a pipeline.
[0019] The features and advantages of the present invention will be readily apparent to those skilled in the art. While numerous changes may be made by those skilled in the art, such changes are within the spirit of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] These drawings illustrate certain aspects of some of the embodiments of the present invention, and should not be used to limit or define the invention.
[0021] FIGURE 1 illustrates the rheological properties of a treatment fluid of the present invention.
[0022] FIGURE 2 illustrates the transmittance properties of clarified diutan and nonclarified diutan
[0023] FIGURE 3 illustrates the friction reduction properties of a treatment fluid of the present invention.
DESCRIPTION OF PREFERRED EMBODIMENTS
[0024] The present invention relates to methods and compositions for use in industrial, oilfield, and/or subterranean operations. More particularly, the present invention relates to treatment fluids comprising clarified diutan gelling agents, and their use in industrial, oilfield, geothermal, coal, coal bed methane, and/or subterranean operations.
[0025] While the compositions and methods of the present invention may be suitable for use in a variety of subterranean treatments, they may be particularly useful in treatments for subterranean formations comprising elevated temperatures, such as those above 2000F. One of the many advantages of the treatment fluids of the present invention is that they may comprise decreased levels of residue as compared to traditional viscosified treatment fluids. In some embodiments, the treatment fluids of the present invention may also provide excellent particulate suspension and transport properties at temperatures above 2000F. In addition, the treatment fluids of the present invention may also provide advantages over traditional viscosified treatment fluids in that they may provide enhanced filtration properties, better permeability regain and/or an increased rate of hydration. [0026] The treatment fluids of the present invention generally comprise a base fluid and a gelling agent that comprises clarified diutan. The term "clarified diutan" as used herein refers to a diutan that has improved turbidity and/or filtration properties as compared to nonclarified diutan. In some embodiments, suitable clarified diutans may have been treated with enzymes or the like to remove residual cellular structures, such as cell walls. In some embodiments, suitable clarified diutans may be produced from genetically modified or bioengineered strains of bacteria or other strains of bacteria that allow the clarified diutan to have improved functional properties such as filterability, turbidity, etc. In one embodiment, the clarified diutan may be modified by genetic engineering or bacteria selection or the result of chemical treatment or derivatization of a diutan. An example of such a modification would be where a portion of the diutan is oxidized or hydrolyzed. Suitable clarified diutan may also be present in a form that will only partially hydrate or will not hydrate at ambient temperature. This form of clarified diutan may be chemically modified, chemically coated, genetically modified, or produced from a new strain of bacteria.
[0027] In general, diutan is a polysaccharide, which may be prepared by fermentation of a strain of sphingomonas. Diutan may also be referred to as a polysaccharide designated S-657 and/or S-8 in some literature. Its structure has been elucidated as having a repeat unit of a hexasaccharide with a tetrasaccharide repeat unit in the backbone that comprises glucose and rhamnose units and a di-rhamnose side chain. It is believed to have thickening, suspending, and stabilizing properties in aqueous and/or nonaqueous solutions. Details of the diutan gum structure may be found in an article by Diltz et al., "Location of O-acetyl Groups in S-657 Using the Reductive-Cleavage Method," CARBOHYDRATE RESEARCH, Vol. 331, p. 265-270 (2001), which is hereby incorporated by reference in its entirety. Details of preparing diutan gum may be found in U.S. Pat. No. 5,175,278, which is hereby incorporated by reference in its entirety. A suitable source of diutan that may be chemically treated to obtain clarified diutan is "GEOVIS XT," which is commercially available from Kelco Oil Field Group, Houston, Texas. Another suitable source of clarified diutan is "FDP-S848-07" and "FDP-S849-07," both of which are available from Halliburton Energy Services, Duncan, Oklahoma. Other examples of suitable sources of clarified diutan may include those disclosed in U.S. Patent Application Nos. 2006/0121578 and 2006/0199201, the relevant disclosures of which are herein incorporated by reference.
[0028] The gelling agent comprising clarified diutan may be provided in any form that is suitable for the particular treatment fluid and/or application of the present invention. In certain embodiments, the gelling agent may be provided as a liquid, gel, suspension, and/or solid additive that is admixed or incorporated into a treatment fluid used in conjunction with the present invention. The gelling agent may also be present in a solid particulate form of any size or shape. For example, larger sized particulates of spherical shape may be used, inter alia, to form perforation tunnel blocking particles, similar to perforation pack balls. Similarly, smaller sized particulates may be used, inter alia, as a fluid loss control material that may act to bridge natural fractures or other channels. The gelling agent should be present in a treatment fluid of the present invention in an amount sufficient to impart the desired viscosity (e.g., sufficient viscosity to divert flow, reduce fluid loss, suspend particulates, provide friction reduction, etc.) to a treatment fluid. More specifically, in some embodiments, the amount of gelling agent used in the treatment fluids of the present invention may vary from about 0.25 pounds per 1000 gallons of treatment fluid ("lbs/Mgal") to about 200 Ibs/Mgal. In other embodiments, the amount of gelling agent included in the treatment fluids of the present invention may vary from about 30 Ibs/Mgaϊ to about 80 lbs/Mgal. In another embodiment, about 60 lbs/Mgal of a gelling agent is included in a treatment fluid of the present invention. It should be noted that in well bores comprising bottom hole temperatures of 2000F or more, 70 lbs/Mgal or more of the gelling agent may be beneficially used in a treatment fluid of the present invention. In embodiments in which the amount of clarified diutan approaches 200 lbs/Mgal, the clarified diutan may act to increase the viscosity of the treatment fluid so that the treatment fluid may be used as a diverting fluid, fluid loss pill to seal a formation, or as a chemical pig.
[0029] In some embodiments, a treatment fluid of the present invention comprising a suitable clarified diutan at a 0.1% concentration in deionized water, in a 1 cm optical cell, has a transmittance at 600 nanometers ("nm") wavelength of at least about 65%. In some embodiments, the clarified diutan has a transmittance of at least about 75%. In some embodiments, the clarified diutan has a transmittance of at least about 85%. One of ordinary skill in the art with the benefit of this disclosure will recognize that the transmittance of any particular treatment fluid of the present invention may also vary depending on the addition of certain additives, the composition of the treatment fluid, the degree of hydration of the clarified diutan, the temperature, and the pH of the treatment fluid. For example, ordinary, unclarified diutan such as GEOVIS XT has a transmittance of about 58% or less.
[0030] In some embodiments, a treatment fluid of the present invention comprising a suitable clarified diutan at a 0.1% concentration in deionized water, in a 1 cm optical cell, has a transmittance at 350 nanometers ("nm") wavelength of at least about 20%. In some embodiments, the clarified diutan has a transmittance of at least about 25%. In some embodiments, the clarified diutan has a transmittance of at least about 30%. In some embodiments, the clarified diutan has a transmittance of at least about 40%. In some embodiments, the clarified diutan has a transmittance of at least about 50%. In some embodiments, the clarified diutan has a transmittance of at least about 60%. In some embodiments, the clarified diutan has a transmittance of at least about 70%. In some embodiments, the clarified diutan has a transmittance of at least about 80%. In some embodiments, the clarified diutan has a transmittance of at least about 90%. One of ordinary skill in the art with the benefit of this disclosure will recognize that the transmittance of any particular treatment fluid of the present invention may also vary depending on the addition of certain additives, the composition of the treatment fluid, the degree of hydration of the clarified diutan, the temperature, and the pH of the treatment fluid. For example, ordinary, unclarified diutan such as GEOVIS XT has a transmittance of about 18% or less.
[0031] In other embodiments, a treatment fluid of the present invention comprising a suitable clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) may have a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a ll cm Whatman #50 filter paper having a 2.7 μ pore size. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 35 grams in 5 minutes. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 40 grams in 5 minutes. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 45 grams in 5 minutes. For example, ordinary, unclarified diutan such as GEOVIS XT has a fluid loss of about 25g or less.
[0032] In other embodiments, a treatment fluid of the present invention comprising a suitable clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) may have a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 150 grams in 5 minutes. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 155 grams in 5 minutes. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 160 grams in 5 minutes. For example, ordinary, unclarified diutan such as GEOVIS XT has a fluid loss of about 14Og or less. [0033] In other embodiments, a treatment fluid of the present invention comprising a suitable clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) may have a fluid loss greater than about 115 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 120 grams in 2.5 minutes. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 130 grams in 2.5 minutes. For example, ordinary, unclarified diutan such as GEOVIS XT has a fluid loss of about 11Og or less. In some embodiments, a treatment fluid of the present invention may have a fluid loss greater than about 140 grams in 2.5 minutes. One of ordinary skill in the art with the benefit of this disclosure will recognize that the filtration rate of any particular treatment fluid of the present invention may also vary depending on the addition of certain additives, the composition of the treatment fluid, the degree of hydration of the clarified diutan, the temperature, and the pH of the treatment fluid.
[0034] Suitable base fluids for use in the present invention include aqueous base fluids and nonaqueous base fluids. Suitable aqueous base fluids that may be used in the treatment fluids of the present invention may include fresh water, salt water, brine, seawater, or any other aqueous fluid that, preferably, does not adversely interact with the other components used in accordance with this invention or with the subterranean formation. The aqueous base fluid preferably is present in the treatment fluids of the present invention in an amount sufficient to substantially hydrate the gelling agent to form a viscosified treatment fluid. Suitable nonaqueous base fluids that may be used in the treatment fluids of the present invention may include glycerol, glycol, polyglycols, ethylene glycol, propylene glycol, and dipropylene gylcol methyl ether. Other examples of suitable nonaqueous base fluids that may be used in the present invention are disclosed in U.S. Patent No. 6,632,779, the relevant disclosure of which is herein incorporated by reference. In some embodiments, the base fluid may be present in the treatment fluids of the present invention in an amount in the range from about 5% to 99.99% by volume of the treatment fluid.
[0035] In some embodiments, the base fluids suitable for use in the treatment fluids of the present invention may be foamed (e.g., a liquid that comprises a gas such as nitrogen or carbon dioxide). As used herein, the term "foamed" also refers to co-mingled fluids. In certain embodiments, it may desirable that the base fluid is foamed to, inter alia, reduce the amount of base fluid that is required, e.g. in water sensitive subterranean formations, to reduce fluid loss to the subterranean formation, enhance flow back of fluids, and/or to provide enhanced proppant suspension. In addition, in certain embodiments where the treatment fluids of the present invention are used for fluid diversion, it may be desirable that the treatment be foamed. While various gases can be utilized for foaming the treatment fluids of this invention, nitrogen, carbon dioxide, and mixtures thereof are preferred. In examples of such embodiments, the gas may be present in a treatment fluid of the present invention in an amount in the range of from about 5% to about 98% by volume of the treatment fluid, and more preferably in the range of from about 20% to about 80%. The amount of gas to incorporate into the fluid may be affected by factors including the viscosity of the fluid and wellhead pressures involved in a particular application. One example of a foamed fluid suitable for use with the present invention are those disclosed in U.S. Patent Application Serial No. 11/506,703, the relevant disclosure of which is herein incorporated by reference.
[0036] If desired, the treatment fluids of the present invention may also be used in the form of an emulsion. An example of a suitable emulsion would comprise an aqueous base fluid comprising a clarified diutan gelling agent and a suitable hydrocarbon. In some embodiments, the emulsion may comprise approximately 30% of an aqueous base fluid and 70% of a suitable hydrocarbon. In some embodiments, the external phase of the emulsion would be aqueous. In certain embodiments, it may be desirable to use an emulsion to, inter alia, reduce fluid loss to the subterranean formation, and/or to provide enhanced proppant suspension. Other benefits and advantages to using emulsions in the methods of the present invention will be evident to one of ordinary skill in the art.
[0037] The treatment fluids of the present invention may vary widely in density. One of ordinary skill in the art with the benefit of this disclosure will recognize the particular density that is most appropriate for a particular application. In some embodiments, the density of the non-foamed treatment fluids of the present invention generally may approximate the density of water. In other embodiments, the density of the non-foamed treatment fluids of the present invention generally may range from about 8.3 pounds per gallon ("ppg") to about 20.5 ppg. One of ordinary skill in the art with the benefit of this disclosure will recognize that the density of any particular treatment fluid of the present invention may also vary depending on the addition of certain additives, including, but not limited to, proppant, gas, fluid loss control additives, alcohols, glycols, and/or hydrocarbons. Furthermore, the desired density for a particular treatment fluid may depend on characteristics of the subterranean formation, including, inter alia, the hydrostatic pressure required to control the fluids of the subterranean formation during placement of the treatment fluids, and the hydrostatic pressure which will damage the subterranean formation. For example, if the treatment fluid remains in the well bore, the density of the treatment fluid may be adjusted to, inter alia, prevent the changing of position of a fluid relative to another fluid with a different density, thereby leaving the treatment fluid at the correct placement within the well bore.
[0038] In some embodiments, the treatment fluid may comprise a brine. Brines suitable for use in some embodiments of the present invention may include those that comprise monovalent, divalent, or trivalent cations. Some divalent or trivalent cations, such as magnesium, calcium, iron, and zirconium, may, in some concentrations and at some pH levels, cause undesirable crosslinking of a diutan polymer. If a water source is used which contains such divalent or trivalent cations in concentrations sufficiently high to be problematic, then such divalent or trivalent salts may be removed, either by a process such as reverse osmosis, or by raising the pH of the water in order to precipitate out such salts to lower the concentration of such salts in the water before the water is used. Another method would be to include a chelating agent to chemically bind the problematic ions to prevent their undesirable interactions with the diutan. As used herein, the term "chelating agent" or "chelant" also refers to sequestering agents and the like. Suitable chelants include, but are not limited to, citric acid or sodium citrate. Other chelating agents also are suitable. Brines, where used, may be of any weight. Examples of suitable brines include calcium bromide brines, zinc bromide brines, calcium chloride brines, sodium chloride brines, sodium bromide brines, potassium bromide brines, potassium chloride brines, sodium nitrate brines, sodium formate brines, potassium formate brines, cesium formate brines, magnesium chloride brines, mixtures thereof, and the like. The brine chosen should be compatible with the formation and should have a sufficient density to provide the appropriate degree of well control. Additional salts may be added to a water source, e.g., to provide a brine, and a resulting viscosified treatment fluid, having a desired density. A preferred suitable brine is seawater. The gelling agents of the present invention may be used successfully with seawater.
[0039] Optionally, the gelling agents of the present invention may comprise an additional gelling agent if the use of the clarified diutan and the gelling agent produces a desirable result, e.g., a synergistic effect. In some embodiments, clarified diutan may be used in combination with other gelling agents so that the clarified duitan only imparts its viscosity once the treatment fluid has entered the formation to provide viscosity at elevated temperatures where other gelling agents may no longer provide adequate viscosity. Suitable additional gelling agents may include polysaccharides and galactomannan gums. Depending on the application, one gelling agent may be more suitable than another. One of ordinary skill in the art with the benefit of this disclosure will be able to determine if an additional gelling agent should be included for a particular application based on, for example, the desired viscosity of the treatment fluid and the bottom hole temperature ("BHT") of the well bore.
[0040] In certain embodiments, the treatment fluids of the present invention also may optionally comprise salts, pH control additives, surfactants, breakers, bactericides, crosslinkers, fluid loss control additives, stabilizers, chelants, scale inhibitors, corrosion inhibitors, hydrate inhibitors, clay stabilizers, salt substitutes (such as trimethy] ammonium chloride), relative permeability modifiers (such as HPT- 1™ available from Halliburton Energy Services, Duncan, OK), sulfide scavengers, fibers, nanoparticles, combinations thereof, or the like.
[0041] Salts may optionally be included in the treatment fluids of the present invention for many purposes, including, for reasons related to compatibility of the treatment fluid with the formation and formation fluids. To determine whether a salt may be beneficially used for compatibility purposes, a compatibility test may be performed to identify potential compatibility problems. From such tests, one of ordinary skill in the art with the benefit of this disclosure will be able to determine whether a salt should be included in a treatment fluid of the present invention. Suitable salts include, but are not limited to, calcium chloride, sodium chloride, magnesium chloride, potassium chloride, sodium bromide, potassium bromide, ammonium chloride, sodium formate, potassium formate, cesium formate, mixtures thereof, and the like. The amount of salt that should be added should be the amount necessary for formation compatibility, such as stability of clay minerals, taking into consideration the crystallization temperature of the brine, e.g., the temperature at which the salt precipitates from the brine as the temperature drops.
[0042] Examples of suitable pH control additives which may optionally be included in the treatment fluids of the present invention are bases and/or acid compositions. A pH control additive may be necessary to maintain the pH of the treatment fluid at a desired level, e.g., to improve the effectiveness of certain breakers and to reduce corrosion on any metal present in the well bore or formation, etc. In some instances, it may be beneficial to maintain the pH at neutral or above 7. For example, in certain embodiments, increasing the pH to 7 or above will give additional stability to the fluid at higher temperatures. One of ordinary skill in the art with the benefit of this disclosure will be able to recognize a suitable pH for a particular application.
[0043] In one embodiment, the pH control additive may be an acid composition. Examples of suitable acid compositions may comprise an acid, an acid generating compound, and combinations thereof. Any known acid may be suitable for use with the treatment fluids of the present invention. Examples of acids that may be suitable for use in the present invention include, but are not limited to organic acids (e.g., formic acids, acetic acids, carbonic acids, citric acids, glycolic acids, lactic acids, ethylenediaminetetraacetic acid ("EDTA"), hydroxyethyl ethylenediamine triacetic acid ("HEDTA"), and the like), inorganic acids (e.g., hydrochloric acid, hydrofluoric acid, phosphonic acid, p-toluenesulfonic acid, and the like), and combinations thereof.
[0044] Examples of acid generating compounds that may be suitable for use in the present invention include, but are not limited to, esters, aliphatic polyesters, ortho esters, which may also be known as ortho ethers, poly (ortho esters), which may also be known as poly(ortho ethers), poly(lactides), poly(glycolides), poly(ε-caρrolactones), poly(hydroxybutyrates), ρoly(anhydrides), or copolymers thereof. The term "copolymer" as used herein is not limited to the combination of two polymers, but includes any combination of polymers, e.g., terpolymers and the like. Derivatives and combinations also may be suitable. Other suitable acid-generating compounds include: esters including, but not limited to, ethylene glycol monoformate, ethylene glycol diformate, diethylene glycol diformate, glyceryl monoformate, glyceryl diformate, glyceryl triformate, triethylene glycol diformate and formate esters of pentaerythritol. Other suitable materials may be disclosed in U.S. Patent Nos. 6,877,563 and 7,021,383, the disclosures of which are incorporated by reference.
[0045] The pH control additive also may comprise a base to elevate the pH of the treatment fluid. Generally, a base may be used to elevate the pH of the mixture to greater than or equal to about 7. Having the pH level at or above 7 may have a positive effect on a chosen breaker being used and may also inhibit the corrosion of any metals present in the well bore or formation, such as tubing, sand screens, etc. In addition, having a pH greater than 7 may also impart greater stability to the viscosity of the treatment fluid, thereby enhancing the length of time that viscosity can be maintained. This could be beneficial in certain uses, such as in longer- term well control and in diverting. Any known base that is compatible with the gelling agents of the present invention can be used in the treatment fluids of the present invention. Examples of suitable bases include, but are not limited to, sodium hydroxide, potassium carbonate, potassium hydroxide, sodium carbonate, and sodium bicarbonate. An example of a suitable base is a solution of 25% sodium hydroxide commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradename "MO-67™" pH control agent. Another example of a suitable base solution is a solution of potassium carbonate commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradename "BA-40L™" buffering agent. One of ordinary skill in the art with the benefit of this disclosure will recognize the suitable bases that may be used to achieve a desired pH elevation. [0046] In some embodiments, the treatment fluid may optionally comprise a chelating agent. When added to the treatment fluids of the present invention, the chelating agent may chelate any dissolved iron (or other divalent or trivalent cation) that may be present in the aqueous fluid. Such chelating may prevent such ions from crosslinking the gelling agent molecules. Such crosslinking may be problematic because, inter alia, it may cause filtration problems, injection problems, and/or cause regain permeability problems. Any suitable chelating agent may be used with the present invention. Examples of suitable chelating agents include, but are not limited to, an anhydrous form of citric acid, commercially available under the tradename "Fe-2™" Iron Sequestering Agent from Halliburton Energy Services, Inc., of Duncan, Oklahoma. Another example of a suitable chelating agent is a solution of citric acid dissolved in water, commercially available under the tradename "Fe-2A™" buffering agent from Halliburton Energy Services, Inc., of Duncan, Oklahoma. Other chelating agents that may be suitable for use with the present invention include, inter alia, nitrilotriacetic acid ("NTA"), any foπn of ethylene diamine tetracetic acid ("EDTA"), hydroxyethylethylenediaminetriacetic acid ("HEDTA"), dicarboxymethyl glutamic acid tetrasodium salt ("GLDA"), diethylenetriaminepentaacetic acid ("DTPA"), propylenediaminetetraacetic acid ("PDTA"), ethylenediaminedi(o- hydroxyphenylacetic) acid ("EDDHA"), glucoheptonic acid, gluconic acid, sodium citrate, phosphonic acid, salts thereof, and the like. In some embodiments, the chelating agent may be a sodium or potassium salt. Generally, the chelating agent may be present in an amount sufficient to prevent crosslinking of the gelling agent molecules by any free iron (or any other divalent or trivalent cation) that may be present. In one embodiment, the chelating agent may be present in an amount of from about 0.02% to about 50.0% by weight of the treatment fluid. In another embodiment, the chelating agent is present in an amount in the range of from about 0.02% to about 2.0% by weight of the treatment fluid. One of ordinary skill in the art with the benefit of this disclosure will be able to determine the proper concentration of a chelating agent for a particular application.
[0047] In some embodiments, the treatment fluids of the present invention may include surfactants, e.g., to improve the compatibility of the treatment fluids of the present invention with other fluids (like any formation fluids) that may be present in the well bore. One of ordinary skill in the art with the benefit of this disclosure will be able to identify the type of surfactant as well as the appropriate concentration of surfactant to be used. Suitable surfactants may be used in a liquid or powder form. Where used, the surfactants may be present in the treatment fluid in an amount sufficient to prevent incompatibility with formation fluids, other treatment fluids, or well bore fluids. In an embodiment where liquid surfactants are used, the surfactants are generally present in an amount in the range of from about 0.01% to about 5.0% by volume of the treatment fluid. In one embodiment, the liquid surfactants are present in an amount in the range of from about 0.1% to about 2.0% by volume of the treatment fluid. In embodiments where powdered surfactants are used, the surfactants may be present in an amount in the range of from about 0.001% to about 0.5% by weight of the treatment fluid. Examples of suitable surfactants are non-emulsifiers commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradenames "LOSURF-259™" nonionic nonemulsifϊer, "LOSURP-300™" nonionic surfactant, "LOSURF-357™" nonionic surfactant, and "LOSURP- 400™" surfactant. Another example of a suitable surfactant is a non-emulsifier commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradename "NEA-96M™" Surfactant.
[0048] In some embodiments, the surfactant may be a viscoelastic surfactant. These viscoelastic surfactants may be cationic, anionic, nonionic, amphoteric, or zwitterionic in nature. The viscoelastic surfactants may comprise any number of different compounds, including methyl ester sulfonates (e.g., as described in U.S. Patent Application Nos. 2006/0180310, 2006/0180309, 2006/0183646 and U.S. Patent No. 7,159,659, the relevant disclosures of which are incoiporated herein by reference), hydrolyzed keratin (e.g., as described in United States Patent No. 6,547,871, the relevant disclosure of which is incorporated herein by reference), sulfosuccinates, taurates, amine oxides, ethoxylated amides, alkoxylated fatty acids, alkoxylated alcohols (e.g., lauryl alcohol ethoxylate, ethoxylated nonyl phenol), ethoxylated fatty amines, ethoxylated alkyl amines (e.g., cocoalkylamine ethoxylate), betaines, modified betaines, alkylamidobetaines (e.g., cocoamidopropyl betaine), quaternary ammonium compounds (e.g., trimethyltallowammonium chloride, trimethylcocoammonium chloride), derivatives thereof, and combinations thereof.
[0049] It should be noted that, in some embodiments, it may be beneficial to add a surfactant to a treatment fluid of the present invention as that fluid is being pumped downhole to help eliminate the possibility of foaming. However, in those embodiments where it is desirable to foam the treatment fluids of the present invention, surfactants such as HY-CLEAN (HC-2)™ surface-active suspending agent or AQF-2™ additive, both commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, may be used. Additional examples of foaming agents that may be utilized to foam and stabilize the acidic treatment fluids of this invention include, but are not limited to, betaines, amine oxides, methyl ester sulfonates, alkylamidobetaines such as cocoamidopropyl betaine, alpha-olefm sulfonate, trimethyltallowammonium chloride, C8 to C22 alkylethoxylate sulfate and trimethylcocoammonium chloride. Other suitable surfactants that may or may not be foamers in a particular application that are available from Halliburton Energy Services include: "19N," "G- Sperse Dispersant," "Howco-Suds™" foaming agent, and "A-Sperse™" dispersing aid for acid additives. Other suitable foaming agents and foam stabilizing agents may be included as well, which will be known to those skilled in the art with the benefit of this disclosure.
[0050] In other embodiments, it may be desirable to emulsify the treatment fluid with a hydrocarbon, forming a aqueous phase external emulsion. In these embodiments, an emulsifying surfactant would be used. One example of a suitable emulsifying surfactant includes a nonionic surfactant such as a sorbitan ester. SEM-7™ Emulsifier, available from Halliburton Energy Services in Duncan, Oklahoma is an example of another suitable surfactant. If a surfactant is used, generally an amount from about 0.1% to about 3% based on volume is sufficient. In some embodiments, the emulsion can be mixed and then pumped. In other embodiments, the components can be pumped and then mixed down hole.
[0051] Furthermore, in some embodiments, microemulsion additives may optionally be included in the treatment fluids of the present invention. Examples of suitable microemulsion additives include, but are not limited to, "Pen-88M™" surfactant, "Pen-88HT™" surfactant, "SSO-21E" surfactant, "SSO-21MW™" surfactant, GasPerm 1000™ Microemulsion Surfactant/Solvent Additive, which are all commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma. Other suitable microemulsion additives are MA-845 additive and MA-844 additive, commercially available from CESI Chemical of Duncan, Oklahoma; ShaleSurf 1000 additive, commercially available from Frac Tech Services of Aledo, Texas; and those disclosed in U.S. Patent App. No. 2003/0166472, the relevant disclosure of which is incorporated by reference.
[0052] In some embodiments, the treatment fluids of the present invention may contain bactericides, inter alia, to protect both the subterranean formation as well as the treatment fluid from attack by bacteria. Such attacks may be problematic because they may lower the viscosity of the treatment fluid, resulting in poorer performance, such as poorer sand suspension properties, for example. Any bactericides known in the art are suitable. An artisan of ordinary skill with the benefit of this disclosure will be able to identify a suitable bactericide and the proper concentration of such bactericide for a given application. Where used, such bactericides are present in an amount sufficient to destroy all bacteria that may be present. Examples of suitable bactericides include, but are not limited to, a 2,2-dibromo-3-nitrilopropionamide, commercially available under the tradename "BE-3S™" biocide from Halliburton Energy Services, Inc., of Duncan, Oklahoma, and a 2-bromo-2-nitro- 1 ,3 -propanediol commercially available under the tradename "BE-6™" biocide from Halliburton Energy Services, Inc., of Duncan, Oklahoma. In one embodiment, the bactericides are present in the treatment fluid in an amount in the range of from about 0.001% to about 1.0% by weight of the treatment fluid. In certain embodiments, when bactericides are used in the treatment fluids of the present invention, they may be added to the treatment fluid before the gelling agent is added.
[0053] The treatment fluids of the present invention optionally may comprise a suitable crosslinker to crosslink the clarified diutan gelling agent in the treatment fluid. Crosslinking may be desirable at higher temperatures and/or when the sand suspension properties of a particular fluid of the present invention may need to be altered for a particular purpose. In addition, crosslinking may be beneficial when using the treatment fluids of the present invention to seal formation zones from loss of fluid from the well bore or when used as a pig for pipeline cleaning. Suitable crosslinkers include, but are not limited to, boron derivatives and salts thereof; potassium derivatives, including but not limited to, potassium periodate; ferric iron complexes and compounds; magnesium complexes and compounds; calcium complexes and compounds, barium complexes and compounds, copper complexes and compounds, aluminum complexes and compounds, cadmium complexes and compounds, zinc complexes and compounds, mercury complexes and compounds, nickel complexes and compounds, lead complexes and compounds, chrome (chromium) complexes and compounds, zirconium complexes and compounds; antimony complexes and compounds; and titanium complexes and compounds. Another example of suitable crosslinkers are those disclosed in U.S. Patent Application Serial No. 11/502,656, the relevant disclosure of which is herein incorporated by reference. Any crosslinker that is compatible with the gelling agent may be used. One of ordinary skill in the art with the benefit of this disclosure will recognize when such crosslinkers are appropriate and what* particular crosslinker will be most suitable.
[0054] The treatment fluids of the present invention also may comprise breakers capable of reducing the viscosity of the treatment fluid at a desired time. Examples of such suitable breakers for treatment fluids of the present invention include, but are not limited to, sodium chlorites, hypochlorites, perborate, persulfates, peroxides, including organic peroxides. Other suitable breakers include, but are not limited to, suitable acids and peroxide breakers, delinkers, as well as enzymes that may be effective in breaking diutan. Another example of suitable breakers are those in U.S. Patent Application Serial No. 11/502,656, the relevant disclosure of which is herein incorporated by reference. Preferred examples of peroxide breakers include tert-butyl hydroperoxide and tert-amyl hydroperoxide. A breaker may be included in a treatment fluid of the present invention in an amount and form sufficient to achieve the desired viscosity reduction at a desired time. The breaker may be formulated to provide a delayed break, if desired. For example, a suitable breaker may be encapsulated if desired. Suitable encapsulation methods are known to those skilled in the art. One suitable encapsulation method that may be used involves coating the chosen breakers with a material that will degrade when downhole so as to release the breaker when desired. Resins that may be suitable include, but are not limited to, polymeric materials that will degrade when downhole. The terms "degrade," "degradation," or "degradable" refer to both the two relatively extreme cases of degradation that the degradable material may undergo, i.e., heterogeneous (or bulk erosion) and homogeneous (or surface erosion), and any stage of degradation in between these two. This degradation can be a result of, inter alia, a chemical or thermal reaction or a reaction induced by radiation. Suitable examples of degradable materials include, but are not limited to, polysaccharides such as dextran or cellulose; chitins; chitosans; proteins; aliphatic polyesters; poly(lactides); poly(glycolides); poly(ε-caprolactones); poly(hydroxybutyrates); poly(anhydrides); aliphatic polycarbonates; orthoesters, poly(orthoesters); poly(amino acids); poly(ethylene oxides); and polyphosphazenes. If used, a breaker should be included in a treatment fluid of the present invention in an amount sufficient to facilitate the desired reduction in viscosity in a treatment fluid. For instance, peroxide concentrations that may be used vary from about 0.1 to about 30 gallons of peroxide per 1000 gallons of the treatment fluid.
[0055] Optionally, a treatment fluid of the present invention may comprise an activator or a retarder, inter alia, to optimize the break rate provided by the breaker. Any known activator or retarder that is compatible with the particular breaker used is suitable for use in the present invention. Examples of such suitable activators include, but are not limited to, acid generating materials, chelated iron, copper, cobalt, and reducing sugars. Examples of suitable retarders include sodium thiosulfate, methanol, and diethylene triamine. In some embodiments, the sodium thiosulfate may be used in a range of from about 1 to about 100 lbs/Mgal of treatment fluid. A preferred range may be from about 5 to about 20 lbs/Mgal. An artisan of ordinary skill with the benefit of this disclosure will be able to identify a suitable activator or retarder and the proper concentration of such activator or retarder for a given application.
[0056] The treatment fluids of the present invention also may comprise suitable fluid loss control agents. Such fluid loss control agents may be particularly useful when a treatment fluid of the present invention is being used in a fracturing application or in a fluid used to seal a formation from invasion of fluid from the well bore. Any fluid loss agent that is compatible with the treatment fluids of the present invention is suitable for use in the present invention. Examples include, but are not limited to, starches, silica flour, gas bubbles (energized fluid or foam), benzoic acid, soaps, resin particulates, relative permeability modifiers, degradable gel particulates, diesel dispersed in fluid, and other immiscible fluids. Another example of a suitable fluid loss control additive is one that comprises a degradable material. Suitable examples of degradable materials include polysaccharides such as dextran or cellulose; chitins; chitosans; proteins; aliphatic polyesters; poly(lactides); poly(glycolides); poly(glycolide-co-lactides); poly(ε-caprolactones); poly(3-hydroxybutyrates); poly(3-hydroxybutyrate-co-hydroxyvalerates); poly(anhydrides); aliphatic poly (carbonates); poly(orthoesters); poly(amino acids); poly(ethylene oxides); poly(phosphazenes); derivatives thereof; or combinations thereof. If included, a fluid loss additive should be added to a treatment fluid of the present invention in an amount necessary to give the desired fluid loss control. In some embodiments, a fluid loss additive may be included in an amount of about 5 to about 2000 Ibs/Mgal of the treatment fluid. In some embodiments, the fluid loss additive may be included in an amount from about 10 to about 50 Ibs/Mgal of the treatment fluid. For some liquid additives like diesel, these may be included in an amount from about 0.01% to about 20% by volume; in some embodiments, these may be included in an amount from about 1.0% to about 10% by volume.
[0057] In certain embodiments, a stabilizer may optionally be included in the treatment fluids of the present invention. It may be particularly advantageous to include a stabilizer if a chosen treatment fluid is experiencing a viscosity degradation. One example of a situation where a stabilizer might be beneficial is where the BHT of the well bore is sufficient by itself to break the treatment fluid without the use of a breaker. Suitable stabilizers include, but are not limited to, sodium thiosulfate, methanol, and salts such as formate salts and potassium chloride. Another example of a suitable stabilizer includes surfactants, such as those in U.S. Patent Application Serial No. 11/418,617, the relevant disclosure of which is herein incorporated by reference. Such stabilizers may be useful when the treatment fluids of the present invention are utilized in a subterranean formation having a temperature above about 2000F. If included, a stabilizer may be added in an amount of from about 1 to about 50 Ibs/Mgal of treatment fluid. In other embodiments, a stabilizer may be included in an amount of from about 5 to about 20 Ibs/Mgal of treatment fluid. In certain embodiments where the stabilizer chosen is a salt, the stabilizer may be included in an amount of from about 5 Ibs/Mgal to about saturation of the treatment fluid. In certain embodiments where the stabilizer chosen is a surfactant, the stabilizer may be included in an amount of from about 0.001% to about 5.0% of the treatment fluid.
[0058] Scale inhibitors may be added to the treatment fluids of the present invention, for example, when a treatment fluid of the present invention is not particularly compatible with the formation waters in the formation in which it is being used. This may include water soluble organic molecules with carboxylic acid, aspartic acid, maleic acids, sulphonic acids, phosphonic acid and phosphate esters groups including copolymers, ter- polymers, grafted copolymers, and derivatives thereof. Examples of such compounds include aliphatic phosphonic acids such as diethylene triamine penta (methylene phosphonate) and polymeric species such as polyvinylsulphonate. The scale inhibitor may be in the form of the free acid but is preferably in the form of mono and polyvalent cation salts such as Na, K, Al, Fe, Ca, Mg, NΗ4. Any scale inhibitor that is compatible with the treatment fluid in which it will be used in suitable for use in the present invention. An example of a suitable scale inhibitor is Scalechek LP-55™ scale inhibitor commercially available from Halliburton Energy Services in Duncan, Oklahoma. Another example of a suitable scale inhibitor is LP-65™ scale inhibitor commercially available from Halliburton Energy Services in Duncan, Oklahoma. If used, a scale inhibitor should be included in an amount effective to inhibit scale formation. Suitable amounts of scale inhibitors that may be included in the treatment fluids of the present invention may range from about 0.05 to 100 gallons per about 1000 gallons of the treatment fluid.
[0059] Any particulates such as proppant and/or gravel that are commonly used in subterranean operations may be used in the present invention (e.g., sand, gravel, bauxite, ceramic materials, glass materials, polymer materials, wood, plant and vegetable matter, nut hulls, walnut hulls, cotton seed hulls, cement, fly ash, fibrous materials, composite particulates, hollow spheres and/or porous proppant). It should be understood that the term "particulate," as used in this disclosure, includes all known shapes of materials including substantially spherical materials, oblong, ellipsoid, rod-like, polygonal materials (such as cubic materials), mixtures thereof, and the like. In some embodiments, resin and/or tackifying agent coated particulates may be suitable for use in the treatment fluids of the present invention. In addition, proppants that have been chemically treated or coated may also be used. The term "coated" does not imply any particular degree of coverage of the proppant particulates with the resin and/or tackifying agent. Examples of tackifying agents suitable for coating particulates are described in U.S. Patent Nos. 5,853,048; 5,833,000; 5,582,249; 5,775,425; 5,787,986, 7,131,491 the relevant disclosures of which are herein incorporated by reference. An example of a suitable commercially available tackifying agent is the "SAND WEDGE" product sold by Halliburton Energy Services, Inc. of Duncan, Oklahoma. Examples of resins suitable for coating particulates are described in U.S. Patent Nos. 6,668,926; 6,729,404; and 6,962,200. An example of a suitable commercially available resin is the "EXPEDITE" product sold by Halliburton Energy Services, Inc. of Duncan, Oklahoma. [0060] The treatment fluids of the present may be provided and introduced into the subterranean formation in certain embodiments of the present invention by any means known in the art. The treatment fluid may be prepared at the job site, prepared at a plant or facility prior to use, or certain components of the treatment fluid (e.g., the base fluid and the gelling agent) may be pre-mixed prior to use and then transported to the job site. Certain components of the treatment fluid may be provided as a "dry mix" to be combined with the base fluid and/or other components prior to or during introducing the treatment fluid into the subterranean formation.
[0061] In certain embodiments, the preparation of these treatment fluids of the present invention may be done at the job site in a method characterized as being performed "on the fly." The term "on-the-fly" is used herein to include methods of combining two or more components wherein a flowing stream of one element is continuously introduced into flowing stream of another component so that the streams are combined and mixed while continuing to flow as a single stream as part of the on-going treatment. Such mixing can also be described as "real-time" mixing. In some embodiments of the present invention, the gelling agent comprising clarified diutan may be mixed into the base fluid on the fly.
[0062] In certain embodiments, the treatment fluid may be introduced into the subterranean formation by pumping the treatment fluid into a well bore that penetrates a portion of the subterranean formation. In certain embodiments (e.g., fracturing operations), the treatment fluid may be introduced into the subterranean formation at or above a pressure sufficient to create or enhance one or more fractures in a portion of the subterranean formation.
[0063] In some embodiments, the treatment fluids of the present invention may be placed in a subterranean formation utilizing a hydrajet tool. The hydrajet tool may be capable of increasing or modifying the velocity and/or direction of the flow of a fluid into a subterranean formation from the velocity and/or direction of the flow of that fluid down a well bore. One of the potential advantages of using a hydrajet tool is that a fluid may be introduced adjacent to and localized to specific areas of interest along the well bore without the use of mechanical or chemical barriers. Some examples of suitable hydrajet tools are described in U.S. Patent "Nos. 5,765,642, 5,494,103, and 5,361,856, the relevant portions of which are hereby incorporated by reference.
[0064] In some embodiments in which a hydrajet tool is used, the fluid(s) introduced through the hydrajet tool are introduced at a pressure sufficient to result in the creation of at least one new fracture in the formation. In one example of a hydrajetting operation carried out at an elevated pressure, a hydrajetting tool having at least one fluid jet forming nozzle is positioned adjacent to a formation to be fractured, and fluid is then jetted through the nozzle against the formation at a pressure sufficient to form a cavity, or slot therein to fracture the formation by stagnation pressure in the cavity. Because the jetted fluids would have to flow out of the slot in a direction generally opposite to the direction of the incoming jetted fluid, they are trapped in the slot and create a relatively high stagnation pressure at the tip of a cavity. This high stagnation pressure may cause a micro-fracture to be formed that extends a short distance into the formation. That micro-fracture may be further extended by pumping a fluid into the well bore to raise the ambient fluid pressure exerted on the formation while the formation is being hydrajetted. Such a fluid in the well bore will flow into the slot and fracture produced by the fluid jet and, if introduced into the well bore at a sufficient rate and pressure, may be used to extend the fracture an additional distance from the well bore into the formation.
[0065] The methods and treatment fluids of the present invention may be used during or in preparation for any subterranean operation wherein a fluid may be used. Suitable subterranean operations may include, but are not limited to, drilling operations, hydraulic fracturing treatments, fracturing treatments such as those disclosed in U.S. Patent Application Serial No. 11/506,703, the relevant disclosure of which is hereby incorporated by reference, sand control treatments (e.g., gravel packing), acidizing treatments (e.g., matrix acidizing, fracture acidizing, removal of filter cakes and fluid loss pills), "frac-pack" treatments, well bore clean-out treatments, and other suitable operations where a treatment fluid of the present invention may be useful. The treatment fluids of the present invention may also be used in conjunction with a remedial treatment utilizing vibrational waves, an example of which is dislcosed in U.S. Patent Application No. 2006/0131012, the relevnat disclosure of which is herein incorporated by reference. In addition, the treatment fluids of the present invention may also be used to reduce friction, as a spacer fluid, insulation fluid, as a diverter, as a fluid loss pill, as part of a drilling fluid, as a chemical pig in a well bore, or as a chemical pig in a pipeline. In some embodiments, the treatment fluid may also comprise a cement slurry.
[0066] In one embodiment, the present invention provides a method that comprises: providing a treatment fluid that comprises a base fluid and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into a subterranean formation. In some embodiments, placing the treatment fluid into the subterranean formation comprises placing the treatment fluid into a well bore penetrating the subterranean formation.
[0067] In certain embodiments, the treatment fluid may be introduced into the subterranean formation at or above a pressure sufficient to create or enhance at least one fracture in the subterranean formation. In certain embodiments, the treatment fluid may comprise a plurality of gravel particulates, and the methods may further comprise depositing at least a portion of those particulates in a desired area in a well bore, e.g., to form a gravel pack, provide some degree of sand control in the subterranean formation, and/or prevent the flow of particulates from an unconsolidated portion of the subterranean formation (e.g., a propped fracture) into a well bore.
[0068] In certain embodiments, the present invention provides a method that comprises: providing a treatment fluid that comprises a base fluid, an acid composition and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into a subterranean formation. In some embodiments, these treatment fluids may be introduced into the subterranean formation at or above a pressure sufficient to create or enhance at least one fracture in the subterranean formation.
[0069] To facilitate a better understanding of the present invention, the following examples of certain aspects of some embodiments are given. In no way should the following examples be read to limit, or define, the entire scope of the invention.
EXAMPLES EXAMPLE 1
[0070] Rheological testing was conducted on treatment fluids of the present invention using a Grace M5600 viscometer. Sample 1 was prepared by blending 2 grams of "FDP-S848-07" in 200 milliliters (umL") of 15% hydrochloric acid in a Waring Blender for approximately 10 minutes, with a 10 minute pressure test in the Grace M560O prior to conducting the measurements. Sample 2 was prepared by blending 2 grams of "FDP-S848-07" in 200 milliliters ("mL") of 15% hydrochloric acid in a Waring Blender for approximately 30 minutes, with a 10 minute pressure test in the Grace M5600 prior to conducting the measurements. The comparative sample, Sample 3 was prepared by blending 2 grams of "GEOVIS XT," a non- clarified diutan, in 200 milliliters ("mL") of 15% hydrochloric acid in a Waring Blender for approximately 10 minutes, with a 10 minute pressure test in the Grace M56OO prior to conducting the measurements. Once prepared, the samples were placed in the cup of a Grace M5600 viscometer to determine the viscosity of the sample at several temperatures. The samples were subjected to a shear rate of about 100 sec"1 using a Bl bob with a shear sweep of 40, 100, and 170 sec"1. The sample temperatures were increased from room temperature to approximately 3000F while the viscosities of the samples were measured. The results of this test are displayed in Tables I5 2, and 3 for Samples 1, 2, and 3, respectively.
[0071] In this example, viscosities at several shear rates are measured at varying temperatures to calculate K' and n' as it depends on temperature. The power-law model relating viscosity, η , to shear rate, f , is a two-parameter model given by η = K'γn ~λ , where K' is commonly referred to as the consistency index and n' is the power-law exponent. For n' = 0 the fluid has Newtonian viscosity, for ri > 1 the fluid is shear-thickening, and for 0 < n' < 1 the fluid is shear-thinning. For some shear-thinning fluids, lower values of n' may indicate higher elastic properties.
[0072] FIGURE 1 is a plot of the calculated viscosity (cP) of Sample 1 "FDP- S848-07" and Sample 3 ("GEOVIS XT") at 100 sec'1 vs. temperature (0F).
TABLE l
Figure imgf000025_0001
TABLE 2
Figure imgf000026_0001
TABLE 3
Figure imgf000027_0001
EXAMPLE 2
[0073] To illustrate, inter alia, the transmittance characteristics of a suitable diutan of the present invention, the following procedure was performed. Three sample solutions were prepared by dissolving 0.2 grams of pure diutan powder in 200 mL of deionized water. Sample 4 contained 0.2 grams of "FDP-S849-07," a clarified diutan available from Halliburton Energy Services, Inc., in 200 mL of deionized water. Sample 5 contained 0.2 grams of "FDP- S848-07," a clarified diutan available from Halliburton Energy Services, Inc., in 200 mL of deionized water. Sample 6 contained 0.2 grams of "GEOVIS XT," a nonclarified diutan available from Kelco Oil Field Group, in 200 mL of deionized water. For each sample solution, the deionized water was placed in a Waring blender and the diutan powder was slowly incorporated into the water over approximately ten seconds at 800 to 1,000 revolutions per minute ("rpm")- Each sample was then mixed in the blender for approximately one hour at 1,500 rpm. After approximately one hour, each sample was then centrifuged at room temperature at 1,000 rpm on a bench top centrifuge for approximately fifteen minutes to remove gas bubbles before measuring the transmittance. The transmittance measurement of each sample was then obtained by placing the sample in a UV- Visible spectrophotometer (e.g. Agilent 8453, Agilent Technologies Co.) in a lcm-thick quartz cell (Open-Top UV quartz cell 10 mm, 3.0 ml Vol.) between 190-900 nm wavelength at room temperature. The background spectrum was measured through air, not an empty cell, allowing this spectrum to be automatically subtracted from the sample spectrum. FIGURE 2 illustrates the transmittance properties of clarified diutan and nonclarified diutan.
EXAMPLE 3
[0074] To illustrate, inter alia, the friction reduction characteristics of a treatment fluid of the present invention comprising a suitable clarified diutan, the following procedure was performed. In this test, a 1 -liter solution containing 50 pounds of "FDP-S848-07," available from Halliburton Energy Services, Inc., per 1000 gallons of Duncan tap water was added to 9 liters of Duncan tap water. Friction reduction measurements were collected on the ensuing 10-liter solution with a net concentration of 5 pounds of FDP-S 848-07 per 1000 gallons of Duncan tap water.
[0075] This friction reduction test was performed using a Friction Reduction Meter ("FR Meter") in accordance with the procedure listed below. The FR Meter was a closed loop pipeline apparatus designed to measure the pressure drop across an 8-foot segment of a 13- foot smooth Hastelloy C pipe. The 8-foot test segment of the 13-foot pipe is positioned to significantly minimize pipe entrance and exit effects on the friction pressure measurement. The smooth Hastelloy C pipe had an inner diameter of 0.554 inches. The FR Meter included a storage/mixing tank connected to a fixed speed progressive cavity pump which pumped the test fluid through a magnetic flow meter then through the test pipes and a return line to the storage/mixing tank.
[0076] For this test, 9 liters of Duncan tap water were added to the storage/mixing tank. Next, the pump was run to circulate the tap water for an amount of time sufficient to fill all the pipes with water. Once the pipes were filled with water, the pump was stopped. The data acquisition system was started, and the pump was started after about an additional 10 to 15 seconds. The data acquisition system measured the flow rate, tank temperature, and pressure drop across the 8-foot section of pipe. At about 1 minute into the test, the 1 -liter solution containing 50 pounds of FDP-S848-07 per 1000 gallons of Duncan tap water was added. The test was run for a total of about 20 minutes, with flow rate, tank temperature, and pressure drop across the 8-foot section of pipe recorded at one-second intervals. The pump rate was about 30 liters per minute, or 3 system volumes per minute. For the smooth Hastelloy C pipe, the flow was fully turbulent at a Reynolds Number between 50,000 and 60,000.
[0077] The first minute of data that was collected prior to the addition of the concentrated clarified diutan solution. This was used to verify instrument readings and provide a baseline of data with a known fluid with known friction pressure properties. The pressure drop across the 8-foot section of pipe for the freshwater was calculated from the flow rate and pipe dimensions in accordance with the following formula:
ΔP - Pr~Lf wale" 2geDh wherein ΔPwater is the calculated pressure drop for the water, p is density of water, V is the velocity, L is length, gc is the gravitational constant, and Dh is the pipe diameter. The variable/ was calculated in accordance with the formula below for turbulent flow.
Figure imgf000029_0001
wherein ε is pipe roughness, d is the pipe diameter, and Nne is the Reynolds Number (Shacham, M., Isr. Chem. Eng., 8, 7E (1976)). For smooth pipe, ε is zero.
[0078] Following the addition of the concentrated, clarified diutan to the tank, the measured pressure drop, was compared to the calculated pressure drop for the water to determine the % Friction Reduction ("% FR") using the following equation:
% FR = 1 - AP measured
wherein APwater is the calculated pressure drop for the water and ΔFmeaSwed is the measured pressure drop after introduction of the solution containing FDP-S848-O7.
[0079] The results of this test plotting % Friction Reduction versus time are shown in FIGURE 3. During the first 10 to 15 seconds, data was collected with the pump off. Afterwards, the pump was turned on, and data was collected on Duncan tap water. Here % Friction Reduction should be approximately zero as ΔP measured should equal ΔPτrøto- After one minute, the solution containing FDP-S848-07 was added, and as a result of the friction reduction properties of FDP-S848-07, % Friction Reduction was measured to be between 50 and 60%.
[0080] Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the present invention. In particular, every range of values (of the form, "from about a to about b," or, equivalently, "from approximately a to b," or, equivalently, "from approximately a-b") disclosed herein is to be understood as referring to the power set (the set of all subsets) of the respective range of values, and set forth every range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee.

Claims

CLAIMS:
1. A treatment fluid comprising a base fluid and a gelling agent that comprises clarified diutan.
2. The composition of claim 1 wherein the clarified diutan has a transmittance at 600 nm wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
3. The composition of claim 1 wherein the clarified diutan has a transmittance at 350 nm wavelength of at least about 20% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
4. The composition of claim 1 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a ll cm Whatman #50 filter paper having a 2.7 μ pore size.
5. The composition of claim 1 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
6. The composition of claim 1 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 115 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
7. The composition of claim 1 wherein the gelling agent is present in the treatment fluid in an amount in the range of from about 0.25 lbs/Mgal to about 200 lbs/Mgal.
8. The composition of claim 1 wherein the base fluid is selected from the group consisting of: an aqueous fluid; a nonaqueous fluid selected from the group consisting of glycerol, glycol, ethylene glycol, polyglycols, propylene glycol, dipropylene gylcol methyl ether, and combinations thereof; and combinations thereof.
9. The composition of claim 1 wherein the treatment fluid further comprises an additive selected from the group consisting of: a brine, a salt, a pH control additive, a surfactant, a breaker, a bactericide, a crosslinker, a fluid loss control additive, a stabilizer, a chelant, a scale inhibitor, a corrosion inhibitor, a hydrate inhibitor, a clay stabilizer, a salt substitute, a relative permeability modifier, a sulfide scavengers, fibers, nanoparticles, and combinations thereof.
10. The composition of claim 1 wherein the treatment fluid is selected from the group consisting of: a fracturing fluid, a gravel packing fluid, an acidic fluid, a friction reducing fluid, a spacer fluid, an insulation fluid, a diverting fluid, a fluid loss pill, a scale removal fluid, and a chemical pig.
11. A subterranean treatment fluid comprising a base fluid, a gelling agent that comprises clarified diutan, and an acid composition.
12. The composition of claim 11 wherein the clarified diutan has a transmittance at 600 nm wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
13. The composition of claim 11 wherein the clarified diutan has a transmittance at 350 nm wavelength of at least about 20% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
14. The composition of claim 11 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #50 filter paper having a 2.7 μ pore size.
15. The composition of claim 11 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
16. The composition of claim 11 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 115 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
17. The composition of claim 11 wherein the gelling agent is present in the treatment fluid in an amount in the range of from about 0.25 Ibs/Mgal to about 200 Ibs/Mgal.
18. The composition of claim 11 wherein the base fluid is selected from the group consisting of: an aqueous fluid; a nonaqueous fluid selected from the group consisting of glycerol, glycol, ethylene glycol, polyglycols, propylene glycol, dipropylene gylcol methyl ether, and combinations thereof; and combinations thereof.
19. The composition of claim 11 wherein the acid composition is selected from the group consisting of: an acid, an acid generating compound, and combinations thereof.
20. The method of claim 11 wherein the acid composition is an acid selected from the group consisting of: formic acid, acetic acid, citric acid, glycolic acid, lactic acid, ethylenediaminetetraacetic acid, hydroxyethyl ethylenediamine triacetic acid, hydrochloric acid, hydrofluoric acid, p-toluenesulfonic acid, and combinations thereof.
21. The composition of claim 11 wherein the acid composition is an acid generating compound selected from the group consisting of: esters, aliphatic polyesters, ortho esters, poly (ortho esters), poly(lactides), poly(glycolides), poly(ε-caprolactones), poly(hydroxybutyrates), poly(anhydrides), ethylene glycol monoformate, ethylene glycol diformate, diethylene glycol diformate, glyceryl monoformate, glyceryl diformate, glyceryl triformate, triethylene glycol diformate and formate esters of pentaerythritol, copolymers thereof, derivatives thereof, and combinations thereof.
22. The composition of claim 11 wherein the treatment fluid further comprises an additive chosen from the group consisting of: a brine, a salt, a pH control additive, a surfactant, a breaker, a bactericide, a crosslinker, a fluid loss control additive, a stabilizer, a chelant, a scale inhibitor, a corrosion inhibitor, a hydrate inhibitor, a clay stabilizer, a salt substitute, a relative permeability modifier, a sulfide scavengers, fibers, nanoparticles, and combinations thereof.
23. A subterranean treatment fluid comprising a base fluid, a gelling agent that comprises clarified diutan, and at least a plurality of particulates.
24. The composition of claim 23 wherein the clarified diutan has a transmittance at 600 ran wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
25. The composition of claim 23 wherein the clarified diutan has a transmittance at 350 nm wavelength of at least about 20% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
26. The composition of claim 23 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #50 filter paper having a 2.7 μ pore size.
27. The composition of claim 23 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
28. The composition of claim 23 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 1 15 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
29. The composition of claim 23 wherein the gelling agent is present in the treatment fluid in an amount in the range of from about 0.25 Ibs/Mgal to about 200 Ibs/Mgal.
30. The composition of claim 23 wherein the base fluid is selected from the group consisting of: an aqueous fluid; a nonaqueous fluid selected from the group consisting of glycerol, glycol, ethylene glycol, polyglycols, propylene glycol, dipropylene gylcol methyl ether, and combinations thereof; and combinations thereof.
31. The composition of claim 23 wherein the treatment fluid further comprises an additive chosen from the group consisting of: a brine, a salt, a pH control additive, a surfactant, a breaker, a bactericide, a crosslinker, a fluid loss control additive, a stabilizer, a chelant, a scale inhibitor, a corrosion inhibitor, a hydrate inhibitor, a clay stabilizer, a salt substitute, a relative permeability modifier, a sulfide scavengers, fibers, nanoparticles, and combinations thereof.
32. The composition of claim 23 wherein the particulates are at least partially coated with a resin or a tackifying agent.
33. A method comprising: providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; and introducing the acidic treatment fluid into at least a portion of a subterranean formation.
34. The method of claim 33 wherein the clarified diutan has a transmittance at 600 nm wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
35. The method of claim 33 wherein the clarified diutan has a transmittance at 350 nm wavelength of at least about 20% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
36. The method of claim 33 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 1 1.5 pounds per gallon (ppg) has a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a ll cm Whatman #50 filter paper having a 2.7 μ pore size.
37. The method of claim 33 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
38. The method of claim 33 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 1 1.5 pounds per gallon (ppg) has a fluid loss greater than about 115 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
39. The method of claim 33 wherein the gelling agent is present in the acidic treatment fluid in an amount in the range of from about 0.25 lbs/Mgal to about 200 lbs/Mgal.
40. The method of claim 33 wherein the acid composition is selected from the group consisting of: an acid, an acid generating compound, and combinations thereof.
41. The method of claim 33 wherein the acid composition is an acid selected from the group consisting of: formic acid, acetic acid, citric acid, carbonic acid, glycolic acid, lactic acid, ethylenediaminetetraacetic acid, hydroxyethyl ethylenediamine triacetic acid, hydrochloric acid, hydrofluoric acid, p-toluenesulfonic acid, and combinations thereof.
42. The method of claim 33 wherein the acid composition is an acid generating compound selected from the group consisting of: esters, aliphatic polyesters, ortho esters, poly (ortho esters), poly(lactides), poly(glycolides), poly(ε-caprolactones), poly(hydroxybutyrates), poly(anhydrides), ethylene glycol monoformate, ethylene glycol diformate, diethylene glycol diformate, glyceryl monoformate, glyceryl diformate, glyceryl triformate, triethylene glycol diformate and formate esters of pentaerythritol, copolymers thereof, derivatives thereof, and combinations thereof.
43. The method of claim 33 wherein the acidic treatment fluid further comprises an additive chosen from the group consisting of: a brine, a salt, a pH control additive, a surfactant, a breaker, a bactericide, a crosslinker, a fluid loss control additive, a stabilizer, a chelant, a scale inhibitor, a corrosion inhibitor, a hydrate inhibitor, a clay stabilizer, a salt substitute, a relative permeability modifier, a sulfide scavengers, fibers, nanoparticles, and combinations thereof.
44. The method of claim 33 further comprising introducing the acidic treatment fluid into at least a portion of a subterranean formation at a pressure sufficient to create or enhance at least one fracture in the subterranean formation.
45. The method of claim 33 wherein the treatment fluid is placed in the subterranean formation with a hydrajet tool.
46. A method comprising: providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; contacting a portion of a subterranean formation with the acidic treatment fluid; and allowing the acidic treatment fluid to interact with a component of the subterranean formation so that the component is at least partially dissolved.
47. The method of claim 46 wherein the clarified diutan has a transmittance at 600 nm wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
48. The method of claim 46 wherein the clarified diutan has a transmittance at 350 nm wavelength of at least about 20% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
49. The method of claim 46 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a l l cm Whatman #50 filter paper having a 2.7 μ pore size.
50. The method of claim 46 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 1 1.5 pounds per gallon (ppg) has a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
53. The method of claim 46 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 1 1.5 pounds per gallon (ppg) has a fluid loss greater than about 115 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 1 1 cm Whatman #2 filter paper having a 8 μ pore size.
52. The method of claim 46 wherein the gelling agent is present in the treatment fluid in an amount in the range of from about 0.25 Ibs/Mgal to about 200 lbs/Mgal.
53. The method of claim 46 wherein the acid composition is selected from the group consisting of: an acid, an acid generating compound, and combinations thereof.
54. The method of claim 46 wherein the acid composition is an acid selected from the group consisting of: formic acid, acetic acid, citric acid, carbonic acid, glycolic acid, lactic acid, ethylenediaminetetraacetic acid, hydroxyethyl ethylenediamine triacetic acid, hydrochloric acid, hydrofluoric acid, p-toluenesulfonic acid, and combinations thereof.
55. The method of claim 46 wherein the acid composition is an acid generating compound selected from the group consisting of: esters, aliphatic polyesters, ortho esters, poly (ortho esters), poly(lactides), poly(glycolides), poly(ε-caprolactones), poly(hydroxybutyrates), poly(anhydrides), ethylene glycol monoformate, ethylene glycol diformate, diethylene glycol diformate, glyceryl monoformate, glyceryl diformate, glyceryl triformate, triethylene glycol diformate and formate esters of pentaerythritol, copolymers thereof, derivatives thereof, and combinations thereof.
56. The method of claim 46 wherein the acidic treatment fluid further comprises an additive chosen from the group consisting of: a brine, a salt, a pH control additive, a surfactant, a breaker, a bactericide, a crosslinker, a fluid loss control additive, a stabilizer, a chelant, a scale inhibitor, a corrosion inhibitor, a hydrate inhibitor, a clay stabilizer, a salt substitute, a relative permeability modifier, a sulfide scavengers, fibers, nanoparticles, and combinations thereof.
57. A method comprising: providing a acidic treatment fluid that comprises a base fluid, an acid composition, and a gelling agent that comprises clarified diutan; and introducing the treatment fluid into a pipeline.
58. The method of claim 57 wherein the clarified diutan has a transmittance at 600 nm wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in de ionized water.
59. The method of claim 57 wherein the gelling agent is present in the treatment fluid in an amount in the range of from about 0.25 lbs/Mgal to about 200 lbs/Mgal.
60. The method of claim 57 wherein the acid composition is selected from the group consisting of: an acid, an acid generating compound, and combinations thereof.
61. The method of claim 57 wherein the acid composition is an acid selected from the group consisting of: formic acid, acetic acid, citric acid, carbonic acid, glycolic acid, lactic acid, ethylenediaminetetraacetic acid, hydroxyethyl ethylenediamine triacetic acid, hydrochloric acid, hydrofluoric acid, p-toluenesulfonic acid, and combinations thereof.
62. The method of claim 57 wherein the acid composition is an acid generating compound selected from the group consisting of: esters, aliphatic polyesters, ortho esters, poly (ortho esters), poly(lactides), poly(glycolides), poly(ε-caprolactones), poly(hydroxybutyrates), poly(anhydrides), ethylene glycol monoformate, ethylene glycol diformate, diethylene glycol diformate, glyceryl monoformate, glyceryl diformate, glyceryl triformate, triethylene glycol diformate and formate esters of pentaerythritol, copolymers thereof, derivatives thereof, and combinations thereof.
63 A method of treating a subterranean formation comprising: providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into at least a portion of a subterranean formation.
64. The method of claim 63 wherein the clarified diutan has a transmittance at 600 nm wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
65. The method of claim 63 wherein the clarified diutan has a transmittance at 350 nm wavelength of at least about 20% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
66. The method of claim 63 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 1 1 cm Whatman #50 filter paper having a 2.7 μ pore size.
67. The method of claim 63 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
68. The method of claim 63 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 1 1.5 pounds per gallon (ppg) has a fluid loss greater than about 115 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
69. The method of claim 63 wherein the gelling agent is present in the treatment fluid in an amount in the range of from about 0.25 lbs/Mgal to about 200 Ibs/Mgal.
70. The method of claim 63 wherein the base fluid is selected from the group consisting of: an aqueous fluid; a nonaqueous fluid selected from the group consisting of glycerol, glycol, ethylene glycol, polyglycols, propylene glycol, dipropylene gylcol methyl ether, and combinations thereof; and combinations thereof.
71. The method of claim 63 wherein the treatment fluid is foamed.
72. The method of claim 63 wherein the treatment fluid is an emulsion.
73. The method of claim 63 wherein the treatment fluid further comprises an additive selected from the group consisting of: a brine, a salt, a pH control additive, a surfactant, a breaker, a bactericide, a crosslinker, a fluid loss control additive, a stabilizer, a chelant, a scale inhibitor, a corrosion inhibitor, a hydrate inhibitor, a clay stabilizer, a salt substitute, a relative permeability modifier, a sulfide scavengers, fibers, nanoparticles, and combinations thereof.
74. The method of claim 63 wherein the treatment fluid is selected from the group consisting of: a fracturing fluid, a gravel packing fluid, an acidic fluid, a friction reducing fluid, a spacer fluid, an insulation fluid, a diverting fluid, a fluid loss pill, a scale removal fluid, and a chemical pig.
75. The method of claim 63 wherein the treatment fluid further comprises particulates.
76. The method of claim 75 further comprising depositing at least a portion of those particulates in a desired area in a well bore to foπn a gravel pack.
77. A method comprising: providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and placing the treatment fluid into at least a portion of a subterranean formation at a pressure sufficient to create or enhance at least one fracture in the subterranean fonnation.
78. The method of claim 77 wherein the clarified diutan has a transmittance at 600 nm wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
79. The method of claim 77 wherein the clarified diutan has a transmittance at 350 nm wavelength of at least about 20% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
80. The method of claim 77 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #50 filter paper having a 2.7 μ pore size.
81. The method of claim 77 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
82. The method of claim 77 wherein the clarified diutan in an amount of 42 lbs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 115 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
83. The method of claim 77 wherein the gelling agent is present in the treatment fluid in an amount in the range of from about 0.25 lbs/Mgal to about 200 lbs/Mgal.
84. The method of claim 77 wherein the base fluid is selected from the group consisting of: an aqueous fluid; a nonaqueous fluid selected from the group consisting of glycerol, glycol, ethylene glycol, polyglycols, propylene glycol, dipropylene gylcol methyl ether, and combinations thereof; and combinations thereof.
85. The method of claim 77 wherein the treatment fluid is foamed.
86. The method of claim 77 wherein the treatment fluid is an emulsion.
87. The method of claim 77 wherein the treatment fluid further comprises an additive selected from the group consisting of: a brine, a salt, a pH control additive, a surfactant, a breaker, a bactericide, a crosslinker, a fluid loss control additive, a stabilizer, a chelant, a scale inhibitor, a corrosion inhibitor, a hydrate inhibitor, a clay stabilizer, a salt substitute, a relative permeability modifier, a sulfide scavengers, fibers, nanoparticles, and combinations thereof.
88. The method of claim 77 wherein the treatment fluid further comprises at least a plurality of particulates.
89. The method of claim 88 wherein the particulates are at least partially coated with a resin or a tackifying agent.
90. The method of claim 77 wherein the treatment fluid is placed in the subterranean formation with a hydrajet tool.
91. A method comprising: providing a treatment fluid comprising a base fluid and a gelling agent that comprises a clarified diutan; and introducing the treatment fluid into a pipeline.
92. The method of claim 91 wherein the clarified diutan has a transmittance at 600 nm wavelength of at least about 65% in a 1 centimeter optical cell, at 0.1% concentration in deionized water.
93. The method of claim 91 wherein the clarified diutan has a transmittance at 350 nm wavelength of at least about 20% in a 1 centimeter optical cell, at 0.1 % concentration in deionized water.
94. The method of claim 91 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 1 1.5 pounds per gallon (ppg) has a fluid loss greater than about 30 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #50 filter paper having a 2.7 μ pore size.
95. The method of claim 91 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 145 grams in 5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
96. The method of claim 91 wherein the clarified diutan in an amount of 42 Ibs/Mgal in a sodium bromide brine having a density of 11.5 pounds per gallon (ppg) has a fluid loss greater than about 1 15 grams in 2.5 minutes at ambient temperature in a filtering laboratory test on a Baroid Filter Press using 40 psi of differential pressure and a 11 cm Whatman #2 filter paper having a 8 μ pore size.
97. The method of claim 91 wherein the gelling agent is present in the treatment fluid in an amount in the range of from about 0.25 Ibs/Mgal to about 200 Ibs/Mgal.
98. The method of claim 91 wherein the base fluid is selected from the group consisting of: an aqueous fluid; a nonaqueous fluid selected from the group consisting of glycerol, glycol, ethylene glycol, polyglycols, propylene glycol, dipropylene gylcol methyl ether, and combinations thereof; and combinations thereof.
99. The method of claim 91 wherein the treatment fluid is foamed.
100. The method of claim 91 wherein the treatment fluid is an emulsion.
101. The method of claim 91 wherein the treatment fluid further comprises an additive selected from the group consisting of: a brine, a salt, a pH control additive, a surfactant, a breaker, a bactericide, a crosslinker, a fluid loss control additive, a stabilizer, a chelant, a scale inhibitor, a corrosion inhibitor, a hydrate inhibitor, a clay stabilizer, a salt substitute, a relative permeability modifier, a sulfide scavengers, fibers, nanoparticles, and combinations thereof.
PCT/GB2008/000474 2007-02-08 2008-02-08 Treatment fluids comprising diutan and associated methods WO2008096164A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0807216-7A2A BRPI0807216A2 (en) 2007-02-08 2008-02-08 TREATMENT FLUID, AND METHOD FOR TREATING AN UNDERGROUND FORMATION
AU2008212688A AU2008212688B2 (en) 2007-02-08 2008-02-08 Treatment fluids comprising diutan and associated methods
CN200880010376.3A CN101675141B (en) 2007-02-08 2008-02-08 Treatment fluids comprising diutan and associated methods
CA2677462A CA2677462C (en) 2007-02-08 2008-02-08 Treatment fluids comprising diutan and associated methods
EP08709370A EP2118233A2 (en) 2007-02-08 2008-02-08 Treatment fluids comprising diutan and associated methods

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/704,598 US7910524B2 (en) 2007-02-08 2007-02-08 Treatment fluids comprising diutan and associated methods
US11/704,598 2007-02-08
US11/704,009 US7960315B2 (en) 2007-02-08 2007-02-08 Treatment fluids comprising diutan and associated methods
US11/704,009 2007-02-08
US11/704,121 2007-02-08
US11/704,121 US20080194428A1 (en) 2007-02-08 2007-02-08 Treatment fluids comprising diutan and associated methods

Publications (2)

Publication Number Publication Date
WO2008096164A2 true WO2008096164A2 (en) 2008-08-14
WO2008096164A3 WO2008096164A3 (en) 2008-11-20

Family

ID=39345620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000474 WO2008096164A2 (en) 2007-02-08 2008-02-08 Treatment fluids comprising diutan and associated methods

Country Status (8)

Country Link
US (3) US7960315B2 (en)
EP (1) EP2118233A2 (en)
CN (1) CN101675141B (en)
AU (1) AU2008212688B2 (en)
BR (1) BRPI0807216A2 (en)
CA (1) CA2677462C (en)
MY (1) MY148586A (en)
WO (1) WO2008096164A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191062A1 (en) * 2014-06-11 2015-12-17 Halliburton Energy Services, Inc. Low density oil external emulsion with gelled internal phase as a gravel packing carrier fluid
US9970246B2 (en) 2012-04-09 2018-05-15 M-I L.L.C. Triggered heating of wellbore fluids by carbon nanomaterials
WO2020181355A1 (en) * 2019-03-12 2020-09-17 Fluid Energy Group Ltd. Use of arylsulfonic acid in oil industry activities

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595282B2 (en) * 2004-05-20 2009-09-29 Halliburton Energy Services, Inc. Methods and compositions of controlling the rheology of a diutan-containing well treatment fluid at high temperatures
US7833949B2 (en) * 2005-01-24 2010-11-16 Schlumberger Technology Corporation Polysaccharide treatment fluid and method of treating a subterranean formation
US8367589B2 (en) * 2005-01-24 2013-02-05 Schlumberger Technology Corporation Polysaccharide treatment fluid and method of treating a subterranean formation
US8567503B2 (en) * 2006-08-04 2013-10-29 Halliburton Energy Services, Inc. Composition and method relating to the prevention and remediation of surfactant gel damage
US9120964B2 (en) 2006-08-04 2015-09-01 Halliburton Energy Services, Inc. Treatment fluids containing biodegradable chelating agents and methods for use thereof
US8567504B2 (en) 2006-08-04 2013-10-29 Halliburton Energy Services, Inc. Composition and method relating to the prevention and remediation of surfactant gel damage
US9027647B2 (en) 2006-08-04 2015-05-12 Halliburton Energy Services, Inc. Treatment fluids containing a biodegradable chelating agent and methods for use thereof
US9127194B2 (en) 2006-08-04 2015-09-08 Halliburton Energy Services, Inc. Treatment fluids containing a boron trifluoride complex and methods for use thereof
US7960315B2 (en) 2007-02-08 2011-06-14 Halliburton Energy Services, Inc. Treatment fluids comprising diutan and associated methods
US8006760B2 (en) 2008-04-10 2011-08-30 Halliburton Energy Services, Inc. Clean fluid systems for partial monolayer fracturing
US7814980B2 (en) * 2008-04-10 2010-10-19 Halliburton Energy Services, Inc. Micro-crosslinked gels and associated methods
US20100096139A1 (en) 2008-10-17 2010-04-22 Frac Tech Services, Ltd. Method for Intervention Operations in Subsurface Hydrocarbon Formations
US9222013B1 (en) 2008-11-13 2015-12-29 Cesi Chemical, Inc. Water-in-oil microemulsions for oilfield applications
US7998910B2 (en) * 2009-02-24 2011-08-16 Halliburton Energy Services, Inc. Treatment fluids comprising relative permeability modifiers and methods of use
US7923414B2 (en) * 2009-08-04 2011-04-12 Schlumberger Technology Corporation Rheology modifier comprising a tetrakis(hydroxyalkyl) phosphonium salt for polymer fluids
WO2011046670A1 (en) * 2009-10-16 2011-04-21 Exxonmobil Upstream Research Company Hydrocarbon recovery operations fluids and methods for using the same
US8276663B2 (en) 2010-09-28 2012-10-02 Halliburton Energy Services Inc. Methods for reducing biological load in subterranean formations
US9587165B2 (en) 2010-10-18 2017-03-07 Saudi Arabian Oil Company Non-damaging bimodal stimulation composition and method of use thereof
US20120090848A1 (en) * 2010-10-19 2012-04-19 Halliburton Energy Services, Inc. Modification of solid polysaccharide with transesterification agent
US20120090846A1 (en) * 2010-10-19 2012-04-19 Halliburton Energy Services, Inc. Modification of solid polysaccharide with transesterification agent
US8418762B2 (en) 2010-11-24 2013-04-16 Baker Hughes Incorporated Method of using gelled fluids with defined specific gravity
US8927467B2 (en) 2010-12-13 2015-01-06 Saudi Arabian Oil Company Method for preventing calcium citrate precipitation during citric acid acidizing treatments
US8496061B2 (en) * 2011-01-19 2013-07-30 Saudi Arabian Oil Company VDA/acid system for matrix acid stimulation
US8881823B2 (en) 2011-05-03 2014-11-11 Halliburton Energy Services, Inc. Environmentally friendly low temperature breaker systems and related methods
US9016375B2 (en) 2011-11-30 2015-04-28 Halliburton Energy Services, Inc. Breaking diutan with oxalic acid at 180° F to 220° F
CN102443386A (en) * 2011-12-13 2012-05-09 中国石油集团川庆钻探工程有限公司井下作业公司 Energy enhancing steering acid liquid system
US20130203637A1 (en) * 2012-02-02 2013-08-08 D. V. Satyanarayana Gupta Method of delaying crosslinking in well treatment operation
MX2014010101A (en) * 2012-02-22 2014-09-16 Tucc Technology Llc Hybrid aqueous-based suspensions for hydraulic fracturing operations.
US9334716B2 (en) 2012-04-12 2016-05-10 Halliburton Energy Services, Inc. Treatment fluids comprising a hydroxypyridinecarboxylic acid and methods for use thereof
DK2838970T3 (en) 2012-04-15 2017-03-20 Flotek Chemistry Llc Density formulations for foam filling
US9200192B2 (en) 2012-05-08 2015-12-01 Cesi Chemical, Inc. Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US11407930B2 (en) 2012-05-08 2022-08-09 Flotek Chemistry, Llc Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US9296943B2 (en) 2012-05-22 2016-03-29 Schlumberger Technology Corporation Subterranean treatment fluid composition and method of treatment
US20130333886A1 (en) 2012-06-19 2013-12-19 Halliburton Energy Services, Inc. Breaking diutan with metal activitor down to 140 °f or lower
US20140090833A1 (en) * 2012-09-28 2014-04-03 Halliburton Energy Services, Inc. Methods for Treating Wellbore and Wellbore Operation Fluids
US10590332B2 (en) 2013-03-14 2020-03-17 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US9068108B2 (en) 2013-03-14 2015-06-30 Cesi Chemical, Inc. Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US9428683B2 (en) 2013-03-14 2016-08-30 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10421707B2 (en) 2013-03-14 2019-09-24 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US10717919B2 (en) 2013-03-14 2020-07-21 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10577531B2 (en) 2013-03-14 2020-03-03 Flotek Chemistry, Llc Polymers and emulsions for use in oil and/or gas wells
US11254856B2 (en) 2013-03-14 2022-02-22 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10000693B2 (en) 2013-03-14 2018-06-19 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US11180690B2 (en) 2013-03-14 2021-11-23 Flotek Chemistry, Llc Diluted microemulsions with low surface tensions
US9868893B2 (en) 2013-03-14 2018-01-16 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9464223B2 (en) 2013-03-14 2016-10-11 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10941106B2 (en) 2013-03-14 2021-03-09 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US10053619B2 (en) 2013-03-14 2018-08-21 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US9884988B2 (en) 2013-03-14 2018-02-06 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9321955B2 (en) 2013-06-14 2016-04-26 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10287483B2 (en) 2013-03-14 2019-05-14 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol
US9670399B2 (en) 2013-03-15 2017-06-06 Halliburton Energy Services, Inc. Methods for acidizing a subterranean formation using a stabilized microemulsion carrier fluid
US20140305647A1 (en) * 2013-04-12 2014-10-16 Halliburton Energy Services, Inc. Methods of producing friction reducing biosynthetic polysaccharides
US20140318774A1 (en) * 2013-04-24 2014-10-30 Halliburton Energy Services, Inc. High Pressure, High Temperature Gravel Pack Carrier Fluid with Extended Dynamic Stability for Alternate Flow Path
US20140378353A1 (en) * 2013-06-24 2014-12-25 Halliburton Energy Services, Inc. Inhibiting Salting Out of Diutan or Scleroglucan in Well Treatment
US9890316B2 (en) 2013-09-12 2018-02-13 Halliburton Energy Services, Inc. Fluid mobility modifiers for increased production in subterranean formations
WO2015065324A1 (en) * 2013-10-29 2015-05-07 Halliburton Energy Services, Inc. Drill-in fluids comprising nanoparticulates for consolidating subterranean formations while drilling
US9890625B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with an obstruction material
US9890624B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with a polymeric material
AU2014390017B2 (en) * 2014-04-09 2017-03-02 Halliburton Energy Services, Inc. Water-soluble linear polyphosphazenes in water-based fluids for use in wells or pipelines
US9505970B2 (en) 2014-05-14 2016-11-29 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US20150330199A1 (en) * 2014-05-15 2015-11-19 Baker Hughes Incorporated Method for enhancing acidizing treatment of a formation having a high bottom hole temperature
US9957779B2 (en) 2014-07-28 2018-05-01 Flotek Chemistry, Llc Methods and compositions related to gelled layers in oil and/or gas wells
CN105900210B (en) * 2014-12-15 2021-06-01 应用材料公司 Method for texturing a chamber component and chamber component with textured surface
CN105349130B (en) * 2015-12-10 2018-02-02 中国石油大学(华东) It is suitable for the diutan and surfactant composite oil-displacing system of high temperature and high salt oil deposit
CN105566923B (en) * 2015-12-10 2017-09-12 中国石油大学(华东) A kind of viscoplasticity nanoemulsions and preparation method thereof
GB2564323B (en) 2016-03-24 2022-02-16 Tetra Tech Improving the temperature stability of polyols and sugar alcohols in brines
MX2018011601A (en) 2016-03-24 2019-01-10 Tetra Tech High density, low tct divalent brines and uses thereof.
WO2017165754A1 (en) 2016-03-24 2017-09-28 Tetra, Technlogies, Inc High density, low tct monovalent brines and uses thereof
CN107325798B (en) * 2017-06-13 2019-08-13 中国石油集团渤海钻探工程有限公司 High temperature resistant anti-salt high-density insulating liquid and preparation method thereof
CN107177350B (en) * 2017-06-13 2019-07-12 中国石油集团渤海钻探工程有限公司 High temperature resistant insulating liquid suspension stabilizer
US10934472B2 (en) 2017-08-18 2021-03-02 Flotek Chemistry, Llc Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
US11453817B2 (en) 2017-10-24 2022-09-27 Tetra Technologies, Inc. Stabilization of iodide-containing brines and brine mixtures
US11021645B2 (en) 2017-10-24 2021-06-01 Tetra Technologies, Inc Stabilization and reduction of TCT of divalent iodide-containing brines
US10851278B2 (en) 2017-10-24 2020-12-01 Tetra Technologies, Inc. Stabilization and reduction of TCT of brines containing monovalent iodides
WO2019108971A1 (en) 2017-12-01 2019-06-06 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
CN108708704B (en) * 2018-05-15 2020-03-31 重庆交通大学 Method for reducing filtration loss of coal bed gas reservoir
US11104843B2 (en) 2019-10-10 2021-08-31 Flotek Chemistry, Llc Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency
US11512243B2 (en) 2020-10-23 2022-11-29 Flotek Chemistry, Llc Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods
CN113881423B (en) * 2021-11-10 2022-10-04 南京工业大学 Application of temperature-sensitive heteropolysaccharide polymer in improving petroleum recovery ratio

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3145776A (en) * 1962-07-30 1964-08-25 Halliburton Co Hydra-jet tool
GB1304002A (en) 1969-02-17 1973-01-24
US5175278A (en) 1985-06-28 1992-12-29 Merck & Co., Inc. Heteropolysaccharide S-657
CA2071711A1 (en) 1991-06-28 1992-12-29 Todd Talashek Enhanced solubility of welan gum in ethylene glycol
US5361856A (en) 1992-09-29 1994-11-08 Halliburton Company Well jetting apparatus and met of modifying a well therewith
US5413178A (en) * 1994-04-12 1995-05-09 Halliburton Company Method for breaking stabilized viscosified fluids
US5759964A (en) 1994-09-28 1998-06-02 Halliburton Energy Services, Inc. High viscosity well treating fluids, additives and methods
US5787986A (en) 1995-03-29 1998-08-04 Halliburton Energy Services, Inc. Control of particulate flowback in subterranean wells
US5582249A (en) * 1995-08-02 1996-12-10 Halliburton Company Control of particulate flowback in subterranean wells
US5775425A (en) * 1995-03-29 1998-07-07 Halliburton Energy Services, Inc. Control of fine particulate flowback in subterranean wells
US5833000A (en) 1995-03-29 1998-11-10 Halliburton Energy Services, Inc. Control of particulate flowback in subterranean wells
CA2239864C (en) 1995-12-15 2008-04-15 Monsanto Company Methods for improved rheological control in cementitious systems
US5765642A (en) * 1996-12-23 1998-06-16 Halliburton Energy Services, Inc. Subterranean formation fracturing methods
US6024171A (en) 1998-03-12 2000-02-15 Vastar Resources, Inc. Method for stimulating a wellbore penetrating a solid carbonaceous subterranean formation
US6489270B1 (en) * 1999-01-07 2002-12-03 Daniel P. Vollmer Methods for enhancing wellbore treatment fluids
ATE394490T1 (en) 2000-03-02 2008-05-15 Cp Kelco Us Inc MUTANT BACTERIAL STRAINS FROM THE GENUS SPHINGONOMAS THAT ARE DEFECTIVE IN THE PRODUCTION OF POLYHYDROXYBUTYRATES, AND METHOD FOR THE CLARIFICATION OF SPHINGANS
US6367550B1 (en) 2000-10-25 2002-04-09 Halliburton Energy Service, Inc. Foamed well cement slurries, additives and methods
US6668926B2 (en) * 2002-01-08 2003-12-30 Halliburton Energy Services, Inc. Methods of consolidating proppant in subterranean fractures
US6962200B2 (en) 2002-01-08 2005-11-08 Halliburton Energy Services, Inc. Methods and compositions for consolidating proppant in subterranean fractures
CA2478433C (en) 2002-03-01 2009-12-08 Cesi Chemical, A Flotek Company Composition and process for well cleaning
US6877563B2 (en) * 2003-01-21 2005-04-12 Halliburton Energy Services, Inc. Methods of drilling and completing well bores
US7413010B2 (en) 2003-06-23 2008-08-19 Halliburton Energy Services, Inc. Remediation of subterranean formations using vibrational waves and consolidating agents
US7131491B2 (en) 2004-06-09 2006-11-07 Halliburton Energy Services, Inc. Aqueous-based tackifier fluids and methods of use
US20050261138A1 (en) * 2004-05-20 2005-11-24 Robb Ian D Viscosified treatment fluids comprising scleroglucan or diutan and associated methods
US7547665B2 (en) 2005-04-29 2009-06-16 Halliburton Energy Services, Inc. Acidic treatment fluids comprising scleroglucan and/or diutan and associated methods
US7727937B2 (en) 2004-07-13 2010-06-01 Halliburton Energy Services, Inc. Acidic treatment fluids comprising xanthan and associated methods
US7621334B2 (en) * 2005-04-29 2009-11-24 Halliburton Energy Services, Inc. Acidic treatment fluids comprising scleroglucan and/or diutan and associated methods
US7275596B2 (en) * 2005-06-20 2007-10-02 Schlumberger Technology Corporation Method of using degradable fiber systems for stimulation
FR2878018B1 (en) * 2004-11-18 2008-05-30 Inst Francais Du Petrole METHOD FOR TRANSPORTING A VISCOUS PRODUCT BY FLOW IN A PARIETAL LUBRICATION REGIME
US7494957B2 (en) 2005-01-24 2009-02-24 Schlumberger Technology Corporation Energized fluids and methods of use thereof
US7781380B2 (en) * 2005-01-24 2010-08-24 Schlumberger Technology Corporation Methods of treating subterranean formations with heteropolysaccharides based fluids
CN103087941B (en) 2005-02-04 2015-09-16 Cp凯尔科美国公司 Polysaccharide slime formers forms the target gene disappearance of bacterium
US20060183646A1 (en) 2005-02-15 2006-08-17 Halliburton Energy Services, Inc. Viscoelastic surfactant fluids and associated methods
US7303019B2 (en) 2005-02-15 2007-12-04 Halliburton Energy Services, Inc. Viscoelastic surfactant fluids and associated diverting methods
US7159659B2 (en) * 2005-02-15 2007-01-09 Halliburton Energy Services, Inc. Viscoelastic surfactant fluids and associated acidizing methods
US7299874B2 (en) * 2005-02-15 2007-11-27 Halliburton Energy Services, Inc. Viscoelastic surfactant fluids and associated methods
WO2006117517A2 (en) 2005-04-29 2006-11-09 Halliburton Energy Services, Inc. Acidic treatment fluids comprising scleroglucan and/or diutan and associated methods
US7318474B2 (en) * 2005-07-11 2008-01-15 Halliburton Energy Services, Inc. Methods and compositions for controlling formation fines and reducing proppant flow-back
US7584791B2 (en) 2007-02-08 2009-09-08 Halliburton Energy Services, Inc. Methods for reducing the viscosity of treatment fluids comprising diutan
US7960315B2 (en) 2007-02-08 2011-06-14 Halliburton Energy Services, Inc. Treatment fluids comprising diutan and associated methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9970246B2 (en) 2012-04-09 2018-05-15 M-I L.L.C. Triggered heating of wellbore fluids by carbon nanomaterials
WO2015191062A1 (en) * 2014-06-11 2015-12-17 Halliburton Energy Services, Inc. Low density oil external emulsion with gelled internal phase as a gravel packing carrier fluid
AU2014396819B2 (en) * 2014-06-11 2017-07-27 Halliburton Energy Services, Inc. Low density oil external emulsion with gelled internal phase as a gravel packing carrier fluid
US10240077B2 (en) 2014-06-11 2019-03-26 Halliburton Energy Services, Inc. Low density oil external emulsion with gelled internal phase as a gravel packing carrier fluid
WO2020181355A1 (en) * 2019-03-12 2020-09-17 Fluid Energy Group Ltd. Use of arylsulfonic acid in oil industry activities

Also Published As

Publication number Publication date
CN101675141B (en) 2014-11-05
US20080194427A1 (en) 2008-08-14
US20080194428A1 (en) 2008-08-14
AU2008212688B2 (en) 2013-02-07
US7910524B2 (en) 2011-03-22
WO2008096164A3 (en) 2008-11-20
US7960315B2 (en) 2011-06-14
CA2677462A1 (en) 2008-08-14
AU2008212688A1 (en) 2008-08-14
MY148586A (en) 2013-04-30
US20080194430A1 (en) 2008-08-14
CN101675141A (en) 2010-03-17
CA2677462C (en) 2012-07-31
EP2118233A2 (en) 2009-11-18
BRPI0807216A2 (en) 2014-06-17

Similar Documents

Publication Publication Date Title
CA2677462C (en) Treatment fluids comprising diutan and associated methods
CA2676296C (en) Methods for reducing the viscosity of treatment fluids comprising diutan
CA2694151C (en) Treatment fluids comprising clarified xanthan and associated methods
US8657003B2 (en) Methods of providing fluid loss control or diversion
US20080026957A1 (en) Treatment and Production of Subterranean Formations with Heteropolysaccharides
AU2012355905B2 (en) Method for delayedly crosslinking environmentally friendly fluids
US9016375B2 (en) Breaking diutan with oxalic acid at 180° F to 220° F
RU2530801C2 (en) Polysaccharide fluid for treatment of nearwellbore area and method for treatment of subterranean stratum
Budiman et al. Seawater-Based Fracturing Fluid: A Review
US10047269B2 (en) Treatment fluids comprising finger millet and methods of use
Salgaonkar et al. Breaking diutan with oxalic acid at 180 F to 220 F

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010376.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08709370

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2677462

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008212688

Country of ref document: AU

Ref document number: 2008709370

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008212688

Country of ref document: AU

Date of ref document: 20080208

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0807216

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090807